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Abstract 
 
 Acute myelogenous leukemia (AML) and its precursors are the result of the 
dysregulation of hematopoiesis.  Hematopoiesis proceeds in a stepwise manner, 
beginning with hematopoietic stem cells, continuing to develop into various stages of 
progenitor cells, and finally becoming fully functional blood cells. As this process goes 
awry, immature, functionless cells of the myeloid lineage proliferate out of control. 
Discerning how myeloid progenitor frequency is regulated allows for a better 
understanding of how the process may lose control. Hematopoiesis has been shown to 
depend on genetic and environmental factors. In this work, I have added to this 
knowledge base by providing novel information about genetic and environmental 
components for the regulation of blood cell development. By performing colony forming 
cell (CFC) assays to determine myeloid progenitor cell frequency in 27 strains of mice, 
and using bioinformatics capabilities in the form on SNP-based in silico mapping, I have 
found patterns among genes located in chromosomal loci of interest for regulating this 
phenotype. These patterns suggest that lipid metabolism, insulin sensitivity, and bone 
properties are key regulators of myelopoiesis. Additionally, I have found that 
polyunsaturated fatty acid (FA) content in the diet is a key environmental regulator. Mice 
fed diets rich in omega-3 FAs have significantly lower middle and late stage progenitor 
cell frequency and increased common myeloid progenitor frequency over those fed more 
similarly to the Western diet. Collectively these data suggest that the content of diet, how 
it is metabolized by the body, and how this affects the bone, regulates the frequency of 
myeloid progenitor cells. Further research into these processes may provide novel 
biomarkers for disease progression and improved therapeutic options for AML. 
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Chapter 1: Introduction 
Hematopoiesis 
 Hematopoiesis refers to the process by which blood cells develop. During 
hematopoiesis, a continuum of differentiation exists, such that long term hematopoietic 
stem cells (LT-HSCs) progressively differentiate to produce terminally differentiated 
cells of the blood (Fig1.1). LT-HSCs, which have infinite self-renewal capabilities, 
divide asymmetrically producing short term hematopoietic stem cells (ST-HSCs), which 
have limited self-renewal capacity. ST-HSCs give rise to highly proliferative multipotent 
progenitor cells (MPPs), which differentiate further, giving rise to the common 
progenitors of the lymphoid and myeloid lineages [1-3]. 
 During myelopoiesis, the common myeloid progenitor gives rise to middle stage 
progenitors including granulocyte monocyte progenitors (GMPs) and erythrocyte 
megakaryocyte progenitors (EMPs). These have more limited differentiation potential. 
The common myeloid progenitor also gives rise to the late stage or committed 
progenitors for the formation of basophils and eosinophils. The GMPs can then 
differentiate further to committed progenitors for granulocytes and monocytes, whereas 
EMPs can differentiate further to committed progenitors for erythrocytes and 
megakaryocytes. These progenitors make up the myeloid progenitor cell compartment 
(Fig.1.1) [4]. 
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Figure 1.1: Progenitor cells represent a continuum of differentiated cell types 
derived from the HSC.  Successive stages of differentiation of the lymphoid lineage 
eventually lead to the formation of mature cells, including B and T cells and natural killer 
cells. Successive stages of differentiation of the myeloid lineage eventually lead to 
formation of mature neutrophils, basophils, macrophages, megakaryocytes and 
erythrocytes. The cells within the red background make up the myeloid progenitor cell 
compartment.  Abbreviations: hematopoietic stem cell (HSC), common myeloid 
progenitor cell (CMP), common lymphoid progenitor cell (CLP), erythroid and 
megakaryocyte progenitor cell (EMP), and granulocyte and monocyte progenitor cell 
(GMP).  The committed progenitor cells are abbreviated as follows: neutrophil (MP-N), 
monocyte (MP-M), eosinophil (MP-Es), basophil (MP-B), erythrocyte (MP-E), and 
megakaryocyte (MP-Meg). 
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 This process of blood cell development occurs first within the yolk sac of 
embryos. As development continues, it takes place in the liver, spleen, and lymph nodes. 
As bone marrow develops, it becomes the location of blood development. Maturation and 
activation of lymphoid cells occur in the thymus, spleen, and lymph nodes [5].  Bone 
marrow is found within the interior of bones and exists in two forms. Red marrow 
consists mainly of hematopoietic tissue, and yellow marrow consists mostly of fat cells. 
As aging occurs, more and more red marrow is converted to yellow marrow, but in cases 
of severe blood loss, the body can convert yellow marrow to red marrow to increase 
blood production. The stroma of the bone marrow consists mostly of yellow marrow. 
Additionally it contains fibroblasts, macrophages, adipocytes, osteoblasts, osteoclasts, 
endothelial cells, and mesenchymal stem cells. The stroma of bone marrow forms the 
hematopoietic microenvironment, containing components that can influence the process 
of hematopoiesis [6.7]. 
 Some hematopoietic cells in the bone marrow exist adjacent to endosteal bone 
surface. The endosteum is a thin layer of connective tissue that lines the surface of the 
bony tissue that forms the medullary or bone marrow cavity of long bones.  Endosteum is 
lined primarily by osteoblasts, which are responsible for bone formation and have been 
shown to produce a variety of cytokines including granulocyte colony-stimulating factor 
(G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-
6 (IL-6) [8]. Due to their role in producing these cytokines that are important for 
hematopoietic cell differentiation, it has been hypothesized that osteoblasts are key 
regulators of hematopoiesis [9]. Osteoclasts, on the other hand, are responsible for bone 
resorption. High levels of calcium, magnesium, phosphate and products of collagen are 
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released as osteoclasts break down mineralized bone. Findings from the Kollet laboratory 
suggest that, in stress-induced situations, osteoclasts degrade endosteal components and 
promote the mobilization of hematopoietic progenitor cells [10]. The opposing effects of 
bone-forming osteoblasts and bone-resorbing osteoclasts control the content of bone 
inner wall and the endosteum region and, therefore, the environment surrounding the 
location of hematopoiesis.  
 
Acute myelogenous leukemia and its precursors 
 Hematopoiesis is known to be influenced by genetic and environmental factors. In 
situations in which this process becomes dysfunctional, hematopoietic malignancies may 
develop. Myeloproliferative diseases of the bone marrow are conditions in which excess 
cells of the myeloid lineage are produced. These diseases may develop into 
myelodysplastic syndromes or acute myelogenous leukemia (AML). Myelodysplastic 
syndromes are dysplasias or ineffective production of the myeloid cells in the bone 
marrow. These syndromes have risk for transformation into AML. In AML, precursor 
cells of the myeloid lineage undergo impaired differentiation and clonal expansion. The 
clinical diagnosis for AML occurs when the percentage of these immature and therefore 
functionless cells rises beyond a particular level in the bone marrow (20-30%) [11]. In 
AML, the overproduction of these cells prevents the production of normal functioning 
red and white blood cells. Without the proper amount of functioning red and white blood 
cells, patients become anemic and slow to fight off infections. Understanding why 
immature myeloid cells proliferate rapidly and cease to differentiate is essential in 
understanding why these hematopoietic malignancies can occur. My research is designed 
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to improve this understanding by identifying genetic and environmental factors that 
control the frequency of myeloid progenitor cells in the bone marrow. 
 
Genetics of hematopoiesis  
 A number of genes are involved in controlling the process of hematopoiesis. Hox, 
Stat, and Gata genes in addition to Pu.1, C-myb, Runx1, Slc, IL-3R, and others have 
been shown regulate this process [12-21]. Some of these are also observed in 
chromosomal translocations in leukemias. Hox genes control differentiation, 
proliferation, and cell fate during hematopoiesis [12-14]. Stat-3 and Stat-5 allow for 
survival and differentiation of myeloid hematopoietic cells [15]. Gata-1 and Pu.1 control 
hematopoietic cell fate by antagonizing one another through direct physical interaction 
[16]. Gata-1 promotes erythromegakaryocytic differentiation while Pu.1 regulates 
myelolymphoid differentiation. Gata-1 directly binds to and suppresses Pu.1. Conditional 
knock-out studies have indicated that c-Myb is required for self-renewal of hematopoietic 
stem cells [17].  Runx1 is a master regulator of hematopoiesis [18]. Scl controls 
transcriptional programs during embryonic hematopoiesis and is vital to megakaryocyte 
and erythrocyte development [19-20]. Deletions in IL-3Rare known to cause decreased 
hematopoietic progenitor cell frequency [21]. The chromosomal region containing this 
gene served as a control for our studies as it has been shown that several of the mouse 
strains we included in our studies contain the 5bp deletion in IL-3R that causes low 
myeloid progenitor cell frequency.  
 Chromosomal translocations, deletions, and genetic mutations are common in 
hematopoietic malignancies. Philadelphia chromosome is a reciprocal translocation 
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between chromosomes 9 and 22 resulting in an oncogenic fusion protein, BCR-ABL. 
This translocation occurs in the myeloproliferative disease of chronic myelogenous 
leukemia (CML) [22]. Other myeloproliferative diseases are often associated with 
mutations in JAK2 [23-25]. One type of myelodysplastic syndrome is also associated 
with JAK2 mutations [26]. A particular myelodysplastic syndrome called 5q- syndrome 
is caused by deletions in the long arm of chromosome 5. These deletions cause anemia 
and megakaryocytic dysplasia. AML is associated with characteristic chromosomal 
abnormalities such as translocations between chromosomes 8 and 21 
(RUNX1/RUNX1T1), translocations between chromosomes 1 and 17 (RARA/PML), or 
inversions in chromosome 16 (CBFB/MYH11) among others. These chromosomal 
aberrations are key indicators of disease prognosis. There are also several gene mutations 
that have been shown to influence the outcome of the disease. These genes include Flt3, 
Npm1, and Kit. Flt3 internal tandem duplications are associated with poorer prognosis in 
AML. Npm1 gene mutations are the most frequent genetic alteration found in AML. Kit 
is a cytokine receptor expressed on hematopoietic stem cells and involved in promoting 
stem cell maintenance. Survival rates and relapse risk for AML rely heavily on 
cytogenetic constitutions and the presence of mutations in the genes mentioned above 
[27-30].  
Table 1.1: Survival and relapse rate associations with chromosomal abnormalities 
Risk Category Abnormality 5-year survival Relapse rate 
Good t(8;21), t(15;17), inv(16) 70% 33% 
Intermediate 
Normal, +8, +21, +22, del(7q), del(9q), 
Abnormal 11q23, all other structural or 
numerical changes 
48% 50% 
Poor -5, -7, del(5q), Abnormal 3q, Complex cytogenetics 15% 78% 
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Strategies for the identification of genes contributing to phenotype 
 As genetics has already been shown to play a vital role in regulating self-renewal, 
proliferation, differentiation, survival, and cell fate in hematopoiesis, and genetic 
abnormalities can lead to hematological malignancies like AML, further investigation to 
discover additional susceptibility genes is warranted. There are multiple ways in which 
genetic susceptibility studies are performed. Traditional genome wide association studies 
(GWAS), including traditional quantitative trait loci (QTL) mapping, and in silico 
mapping based on single nucleotide polymorphisms (SNPs) are ways in which this can be 
accomplished. Their power in doing so, however, differs. 
 GWAS typically compare two groups, a disease group and a normal group. 
Genomic DNA is compared for selected markers of variation or SNPs. Genetic variations 
that are more frequent in people with the disease are considered associated with the 
disease. As these studies tend to point to broad genomic regions, researchers must use 
other methods (such as DNA sequencing) to identify the exact genetic change involved in 
the disease [31]. Traditional QTL mapping studies in mice are GWAS that are based on 
the intercrossing of 2 strains of inbred mice that differ for the phenotype of interest. F1 
generation mice are genetically identical to one another and are true hybrids of the 
parental strains. F1 generation mice are then subject to brother-sister mating to form F2 
generation mice, which are phenotypically and genotypically diverse. Phenotype and 
genotype comparisons are made to identify which chromosomal loci correlate with the 
particular phenotype studied. Traditional QTL mapping in mice may use backcrosses as 
well [32]. Backcrossing involves the mating of F1 generation mice back to a parental 
strain.   
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SNP-based in silico mapping studies utilize known SNP information across the 
genome to associate phenotypic data with available genetic information (genotypes). 
However unlike traditional QTL studies, in silico mapping investigates several (≥25) 
mouse strains. These comparisons allow the identification of chromosomal regions 
containing genes responsible for the evaluated phenotype (Fig1.2). The recent availability 
of denser marker sets (sets of known SNP information) has provided greater resolution 
for this technique. Typical QTL studies have a 2-5cM resolution, whereas, in SNP based 
in silico mapping studies, the relatively even spacing of the SNPs every 300kb allows for 
mapping traits within 0.5cM regions [33]. SNP based in silico mapping makes 
comparisons that are based on regions of the genome inherited from common ancestors 
as opposed to traditional QTL studies that rely only on loci inherited from different 
progenitors. Comparison across a greater number of strains provides greater statistical 
power. In addition, SNP based in silico mapping takes into account a wider range of 
phenotypic diversity by utilizing quantitative traits rather than traditional studies that only 
take into account dichotomous (completely opposing) phenotypes, such as presenting 
with a disease or without it. This type of haplotype associated mapping has successfully 
proven to be more powerful in narrowing chromosomal locations containing genes of 
interest than traditional QTL mapping in multiple studies [34, 35]. Table 1.2 summarizes 
the differences in the two approaches. 
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Strain A 
Blue bar represents a particular chromosome
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from Strain A based on SNP data 
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Figure 1.2: Hypothetical examples of how in silico comparisons are made. 
Phenotypic similarities and differences are compared to SNP similarities and differences 
among mouse strains to identify chromosomal regions of interest that control phenotype. 
A. These comparisons take advantage of differences at SNP sites throughout the genome. 
B. These comparisons take advantage of similarities at SNP sites throughout the genome. 
 
Table 1.2: Comparison of genome wide mapping techniques in mice 
 Traditional QTL SNP Based In Silico 
Genetic diversity Utilizes 2 background strains Utilizes ≥25 strains 
Comparisons  Differences of 2 progenitor strains Differences and similarities of ≥25 strains 
Resolution 2-5cM 0.5cM 
  
Some of these strategies have been useful in identifying chromosomal loci 
important to hematopoiesis. QTLs found for hematopoietic stem cell frequency have 
been very large, in the range of 10 or more cMs, when using traditional QTL studies, 
making it difficult to determine genes of importance [36-38]. One group identified 2 
QTLs in regulating hematopoietic parameters in B6AKRF2 mice, which are derived 
from intercrossing AKR and C57BL/6 mice. They found that a QTL in chromosome 
12 regulated neutrophils in the blood and a QTL at chromosome 2 regulated stem 
cell numbers in the bone marrow [39]. Interestingly, the gene Alpq1 was located in 
this region. As you will find in chapter 2, our studies pointed to a region containing 
Alpq3. These genes were both identified in GWAS for alcohol preference [40]. 
Chronic alcohol use induces bone loss through the suppression of Wnt signaling 
[41]. Another group found a region in chromosome 2 important for response of 
progenitors to early cytokines [38]. These studies were limited in that they only 
investigated strains that were progeny of 2 background strains. This same group 
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investigated quantitative genetic variation in the hematopoietic stem cell and 
progenitor cell compartment properties and found them to be associated with life 
span QTLs [42]. Resolution in these studies was much lower than attainable by in 
silico mapping. We show in chapter 2 that in silico mapping offers much higher 
resolution for identifying these regions. Many regions in our study were much 
smaller regions within the previously mentioned QTLs for hematopoietic stem and 
early progenitor cell frequency.  
 
Environment and hematopoiesis 
 Environmental influences have also been shown to influence hematopoiesis and 
risk for hematological malignancies. Radiation, benzene, and cold exposure have been 
shown to affect the process of hematopoiesis in a profound way [43-47].  Atomic bomb 
survivors have a high incidence of myelodysplastic syndromes as well as AML [48]. 
Treatment of other diseases, such as other cancers and ankylosing spondylitis, with 
radiation is also associated with these hematopoietic malignancies [49, 50]. Additionally, 
prior to modern radiation safety precautions, radiologists had increased incidence of 
AML and its precursors [51]. Benzene exposure also contributes to leukemia risk. It has 
toxic effects on bone marrow, such that progenitor cell colony formation is significantly 
declined with increasing benzene exposure [52]. Cold exposure has been shown to down-
regulate the expression of many genes encoding hematopoietic transcription factors 
(Runx1, Scl, C-myb, and Gata-2) and particularly erythropoiesis related factors (Klfd, 
Hbaa1, Ba1, Gata-1, Epo, and Epor). Some myelopoiesis related factors, however, were 
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up-regulated in these low temperature conditions [47]. In chapters 3 and 4, we 
demonstrate that the content of FAs in the diet control myeloid progenitor cell frequency. 
 
Lipids and hematopoiesis 
 Studies for cancer prevention and treatment have in recent years turned to the diet 
as it involves opportunities for natural ways to achieve these goals. Focus has centered on 
FA consumption in the diet and how it affects cancer risk. Particular interest for 
preventative measures as well as treatment options have focused on polyunsaturated fatty 
acids (PUFAs).  
 FAs are carboxylic acids with hydrocarbon chains ranging from 4 to 28 carbons in 
length and varying in their degree of saturation with hydrogen molecules. PUFAs are FAs 
that contain more than one double bond. They are structural components of membrane 
phospholipids and are the precursors to many signaling molecules. Omega-3 (n-3) and 
omega-6 (n-6) are PUFAs in which the n-3 and n-6 refer to the placement of the first 
double bond from the omega end of the FA chain (Fig1.3). n-3 FAs consist primarily of 
-linolenic acid (ALA), eicosapentanoic acid (EPA), and docosahexanoic acid (DHA). In 
several research studies, n-3 FAs have been found to have suppressive effects on cancer 
[53-56]. n-6 FAs consist of linoleic acid (LNA) and arachidonic acid (ARA), among 
others. In many studies, n-6 FAs appear to promote cancer development [53, 55, 57]. n-3 
and n-6 FAs have antagonizing effects in the body. n-6 FA prostaglandins tend to be pro-
inflammatory and pro-proliferative, while n-3 FA prostaglandins are associated with the 
opposite qualities [58]. Suppression of n-6 FA-derived eicosanoids has been proposed as 
a strategy for chemoprevention [59]. As n-3 FAs compete for the same metabolic 
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enzymes as n-6 FAs, the ratio of n-3 to n-6 FAs in the diet is increasingly studied in 
addition to the content of these FAs individually.  
 
Figure 1.3: Examples of n-3 and n-6 fatty acids. A. Eicosapentanoic acid with first 
double bond in n-3 position. B. Arachidonic acid with first double bond in n-6 position.  
 
 The broad category of lipids contains FAs among others. Lipids have function in 
cell membranes, signaling, and energy storage. They have been shown to have several 
effects on hematopoiesis. Prostaglandin E2 (PGE2), derived from ARA, preferentially 
expands ST-HSCs/MPPs [60]. It also decreases macrophage colony stimulating factor 
(M-CSF) production by bone marrow stromal cells [61]. Many studies have shown that 
various lipoxygenases have key roles in regulating hematopoiesis as well [62-64]. 
Lipoxygenases are enzymes that catalyze the oxidation of PUFAs into 
lipidhydroperoxides.  Many lipoxygenase isozymes are involved in the metabolism of 
eicosanoids. Recent studies have also investigated the functions of lysosomal acid lipase 
in hematopoiesis. It has been shown to play a critical role in myelopoiesis during 
hematopoietic development, differentiation, and homeostasis. Lysosomal acid lipase is a 
key enzyme involved in cleaving cholesteryl esters and triglycerides. This cleavage 
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generates free FAs and cholesterol in lysosomes. In lysosomal acid lipase knock out 
mice, there is increased proliferation of HSCs and myeloid progenitor cells. The 
microenvironment in these mice does not support normal hematopoiesis [65]. Valproic 
acid, a clear liquid FA at room temperature, is also involved in control of hematopoiesis. 
This histone deacetylase inhibitor is known to induce differentiation or apoptosis in 
leukemic blast cells. It is also involved in HSC proliferation and enhances the potential of 
interleukin 3 (IL-3) to stimulate megakaryopoiesis and erythropoiesis [66, 68].  
 A role for dietary lipids has been established in hematopoiesis. Ratios of n-3 to n-
6 FAs in the diet have been shown to have effects in prevention or progression 
(depending on the ratio) of cancer [68, 69]. As progenitor cell frequency is important to 
understanding leukemia progression, we decided to investigate how ratios of dietary n-3 
to n-6 FAs affect stem and progenitor cell biology in myelopoiesis. In chapters 3 and 4 
we show that these ratios indeed play a significant role in regulating myeloid progenitor 
cell frequency. 
  
Overall, this work proposes that genetic and environmental factors have related 
roles in controlling myeloid progenitor cell frequency. In chapter 2, we propose that 
genetic factors control hematopoiesis and that they can be identified by investigating 
polymorphisms associated with the control of myeloid progenitor cell frequency among 
inbred mouse strains. Our results suggest that genes that control metabolism and bone 
properties regulate this process. In chapters 3 and 4, we show that the environmental 
factor of the diet plays a significant role in controlling myeloid progenitor cell frequency. 
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Collectively, this work supports the roles of dietary FA content, lipid metabolism, and 
bone properties in regulating hematopoiesis.  
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Abstract 
 Upon discovering that various strains of inbred mice have significantly different 
myeloid progenitor cell pools, we hypothesized that polymorphisms between inbred 
strains could be used to identify genes that regulate myeloid progenitor cell frequency in 
the bone marrow. This information will be useful in understanding how hematopoietic 
malignancies develop. We used hematopoietic progenitor cell assays, determining 
progenitor cell frequency in 27 strains of inbred mice, and single nucleotide 
polymorphism (SNP) based in silico mapping techniques to investigate our hypothesis. 
These techniques returned several chromosomal loci containing cancer and hematological 
disease related genes. Additionally, a control region containing interleukin 3 receptor 
alpha (IL-3Rwhich is known to be involved in controlling myeloid progenitor cell 
frequency, had a strong association with the regulation of this phenotype in these in silico 
mapping studies. Upon meta-analysis of our data, we found that many chromosomal 
regions that presented with strong association or as regions of interest contain genes 
involved in bone formation, bone quality, and bone mechanics as well as lipid 
metabolism and insulin metabolism. These genes of interest suggest a complex 
combination of involvement in the properties of the bone specifically providing a support 
mechanism for the regulation of myeloid progenitor cell frequency. Further investigation 
of these genes may yield novel information as to how hematopoiesis is controlled, and 
therefore why it may go awry in hematopoietic malignancies, such as acute myelogenous 
leukemia. 
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Introduction 
 The process of hematopoiesis has been shown to depend on genetic and 
environmental factors. Fatty acid (FA) composition of the diet, radiation exposure, 
benzene exposure, and cold exposure are all environmental factors that affect this process 
of blood cell development [1-6]. Several genes have also been shown to be involved in 
controlling hematopoiesis. Stat, Gata, and Hox genes as well as Pu.1, Runx1, Scl, IL-
3R, and many more genes have been shown to regulate this process [7-13].  Stat-3 and 
Stat-5 allow for survival and differentiation of myeloid hematopoietic cells [7]. Gata-1 
and Pu.1 control hematopoietic cell fate by antagonizing one another [8]. Hox genes 
control differentiation, proliferation, and cell fate during hematopoiesis [9-11]. Runx1 is a 
master regulator of hematopoiesis [12].  Scl controls transcriptional programs during 
embryonic hematopoiesis and is vital to megakaryocyte and erythrocyte development 
[13-14]. Deletions in IL-3Rare known to cause decreased hematopoietic progenitor cell 
frequency [15]. In our studies, we are continuing the search for genes involved in 
controlling hematopoiesis. 
 Hematopoiesis is a process that occurs in a stepwise manner, beginning with 
hematopoietic stem cells, continuing to develop into various stages of progenitor cells, 
and finally becoming fully functional blood cells. In hematopoietic malignancies, such as 
acute myelogenous leukemia (AML), this process is dysfunctional, allowing for the 
expansion of the myeloid progenitor cell compartment. This compartment contains early 
progenitors called granulocyte erythrocyte megakaryocyte macrophage (GEMM) 
progenitors that have the potential to develop into several blood cell types. It contains 
middle stage progenitors, such as granulocyte macrophage (GM) progenitors, that 
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develop from GEMM progenitors. These middle stage progenitors have less potential 
than their precursors. This compartment also contains late stage or committed 
progenitors, such as erythrocyte (E), granulocyte (G), and macrophage (M) progenitors. E 
progenitors also have GEMM progenitors as a precursor as well as a middle stage 
precursor that cannot be assayed with our colony forming cell (CFC) technique. These 
late stage progenitors, however, can only develop into erythrocytes, which have the 
primary function of delivering oxygen to tissues throughout the body. G and M 
progenitors develop from GM progenitors and only have the potential to develop into 
granulocytes or macrophages, respectively. Granulocytes and macrophages are cells of 
the immune system that defend against infection and foreign materials. Understanding 
more completely how the processes of development and differentiation of these 
progenitor cells are genetically controlled may provide valuable information as to how 
they may malfunction in cancers of the blood and lymph. 
 Myeloproliferative diseases of the bone marrow are conditions that involve an 
excess of progenitor cells of the myeloid lineage being produced. This precursor disease 
may evolve into myelodysplastic syndrome or AML. Myelodysplastic syndromes are 
bone marrow cell disorders in which the ineffective production of myeloid blood cells 
increases risk for transformation to AML. In AML, normal bone marrow is overtaken by 
immature functionless cells of the myeloid lineage, which causes a drop in normal blood 
cells and platelets. Learning how hematopoietic cell frequency is controlled at the 
progenitor cell level is vital to understanding why it becomes altered in these 
hematological disorders. 
25 
 In order to determine how this process is genetically controlled, our lab used 
hematopoietic progenitor cell assays and in silico mapping techniques to identify 
chromosomal regions containing genes that control myeloid progenitor cell frequency 
[16]. We have since increased the number of inbred strains studied from 10 to 27. We 
also enhanced our assay to investigate the frequency of individual progenitor types. In 
silico mapping databases have been improved to include increased sets of known SNP 
information throughout the genome (denser marker sets) as well. This has increased 
statistical power in our studies. 
 
Materials and methods  
Animals 
 All mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Strains 
include 129S1/SvImJ, A/J, AKR/J, BALB/cJ, BALB/cByJ, BTBRT+tf/J, C3H/HeJ, 
C57BL/6J, C57BL/10J, C57BLKS/J, C57BR/cdJ, C57L/J, C58/J, CBA/J, DBA/1J, 
DBA/2J, FVB/NJ, I/lnJ, LP/J, MA/MyJ, NZB/BINJ, NZW/lacJ, PERA/EiJ, PL/J, 
SEA/GnJ, SM/J, and WSB/EiJ. Strains were chosen based on previously published 
results [17]. Only male mice were used to avoid cyclic changes in hormones. Mice were 
housed in the AAALAC accredited animal facilities of the Marshall University School of 
Medicine. All animal use and care was approved by the Marshall University Institutional 
Animal Care and Use Committee. Bone marrow was harvested at 10-14 weeks of age.  
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Colony forming cell assays 
 CFC assays were performed upon bone marrow isolated from mice as previously 
described [16, 18]. Briefly, bone marrow was harvested by flushing from the femurs with 
Iscove’s Modified Dulbecco’s Medium (IMDM), and cells were counted and seeded in 4 
well plates at a density determined empirically by a pilot study conducted with a broad 
and consistent range of seeding densities. After linear response of colony production to 
seeding density was ensured by the pilot study, seeding densities were chosen to produce 
10-30 colonies for each well (4-well plates). Bone marrow was cultured in 1% semi-solid 
Methocult M3434 (StemCell Technologies), supplemented with 0.4% autochthonous 
sera. Cells were incubated for 6-7 days to allow colony formation. Colonies with a 
minimum cell number of 20 were scored as positive using an inverted microscope at 40X 
magnification. Colonies were counted based on morphological features that are 
associated with each progenitor type. 
 
In silico mapping 
 The SNPs used for genome-wide association tests are found in the Mouse 
Diversity Array [19]. A total of 194,363 informative SNPs were used for SNPster and 
efficient mixed model association (EMMA) analysis. Our data set was analyzed using 
SNPster genome-wide association software (http://snpster.gnf.org), which gives a 
phenotype/genotype correlation score in the form of -logp [17, 20]. These -logp scores 
are used to identify regions of the genome that have a high probability of non-random 
correlation.  Heritability was measured based on standard deviation within the strains as 
compared with the variability between strains. This measure of heritability is 
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incorporated in the algorithms used in the analyses. Heritability is rated on a percentage 
scale in which a higher percentage reflects a higher heritability. Figures and tables show -
logp values based on SNPster analysis. Based on the -logp value of the IL-3R control 
region (3.02, p-value of 0.00095) and the need to minimize spurious associations, regions 
with -logp values above 2.5 (p-value of 0.0032), were considered of interest, and regions 
with a -logp value above 2.8 (p-value of 0.0016) were considered of strong association. 
SNPster -logp values are not corrected for multiple comparisons. 
 We also employed the EMMA R package for genome-wide association scans as 
an alternative to SNPster analysis. In this model, restricted maximum likelihood (REML) 
was used to estimate the variance component, which is followed by a t-test. This method 
accounts for strain relatedness to reduce the number of false positives [21]. 
 
Evaluation of Interleukin-3 Receptor Alpha 
 Genomic DNA was obtained from mouse liver. To amplify intron 7 of the murine 
IL-3R gene, 100ng of genomic DNA from each strain and two primers (STP-44 and 
STP-23) were used. The primers used were 5’-AACAGATTCCACCATGGCCTCC-3’ 
(STP-44) and 5’-TCTGACCTCGACTTGACCCGG-3’ (STP-23). PCR was performed by 
31 cycles of 94°C for 1 minute, 53°C for 2 minutes, and 72°C for 3 minutes using 
AmpliTaq Gold Faststart Polymerase (Applied Biosystems). PCR products were digested 
with DdeI endonuclease (Promega) and analyzed on a 2% agarose gel using ethidium 
bromide for detection of bands. A Mann Whitney test (using SigmaPlot) was performed 
on genotypes A and B.   
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Meta-analysis 
 For pathway analysis, we selected the top 50-55 genes within the chromosomal 
regions with the highest -logp values from the in silico mapping analyses. We defined the 
boundaries of the regions of interest as 90% of the highest -logp value in each peak. 
Chromosomal regions were then entered into the Mouse Genome Information database to 
determine the known genes that exist in the regions. The top 50 genes for each phenotype 
were subjected to literature searches as well as Ingenuity Pathway Analysis v8.7 (IPA, 
Ingenuity Systems Inc.) analyses to determine gene properties and network interactions. 
IPA analyzes the combination of genes in signaling networks and statistically evaluates 
the probability of the network against the probability that a network would form at 
random. Networks are subject to a Fisher’s exact test, and those with p-values less than 
0.001 were considered to be significant. Top 50-55 genes lists for each phenotype can be 
found in the addendum. 
 
Results 
 Our previous experiments in investigating the myeloid progenitor compartment in 
multiple strains of inbred mice revealed that myeloid progenitor cell frequency varies 
among strains [16]. Use of in silico mapping to compare these phenotypic similarities and 
differences to the genetic similarities and differences among them was previously limited 
due to a relatively low number of strains studied and less informative databases.  To 
increase the power and specificity of this technique, we have increased the amount of 
strains being studied and refined our assay to study each progenitor type individually as 
well as total progenitor cell frequency.  
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 In silico mapping utilizes SNP information across the genome to compare 
phenotypic information to available genetic information about mouse strains. These 
comparisons allow the identification of chromosomal regions containing genes 
responsible for the evaluated phenotype. The availability of denser marker sets and an 
increased number of strains being studied provided a greater statistical power for this 
technique [19]. 
 Twenty-seven mouse strains were evaluated for myeloid progenitor cell 
frequency. These strains have varied ancestry, thus allowing in silico mapping techniques 
to take advantage of closely related strains as well as strains that are more genotypically 
diverse. The majority of mice were of Castle (129S1/SvImJ, A/J, AKR/J, BALB/cJ, 
BALB/cByJ, C3H/HeJ, CBA/J, DBA/1J, DBA/2J, I/LnJ, LP/J, NZB/BINJ, NZW/lacJ, 
SEA/GnJ, and SM/J) or C-57 related ancestry (C57BL/6J, C57BL/10J, C57BLKS/J, 
C57BR/cdJ, C57L/J , C58/J, and MA/MyJ). Additional strains were of Swiss (FVB/NJ), 
wild(PERA/EiJ and WSB/EiJ), other (PL/J), or unknown (BTBRT+tf/J) ancestry. There 
was no correlation between ancestry and phenotypic data. GEMM, GM, G, M, and E 
progenitor cell frequencies were evaluated as well as total myeloid progenitor cell 
frequency. Phenotypic data was then compared to genotypic information using in silico 
mapping.  
 
Early progenitor frequency and in silico mapping 
 The earliest progenitor type evaluated by CFC assays was the GEMM progenitor. 
This phenotype varied among inbred mouse strains, with a range of 0.005-0.449 
colonies/1000 cells seeded, and an 89.8-fold difference between the strain with the 
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highest progenitor cell frequency and the strain with the lowest progenitor frequency. 
Phenotypic data for GEMM progenitor cell frequency is shown in Figure 2.1A as 
colonies counted per 1000 cells seeded. In silico mapping revealed several regions with  
-logp values above 2.5, and several regions with a -logp value above 2.8. In silico 
mapping results using SNPster software are shown in Figure 2.1B. EMMA analysis was 
also performed for this data. It showed similar results, with the region in chromosome 14 
having significant genome wide association after tests for multiple comparisons. Table 
2.1 shows chromosomal regions with -logp values above 2.5, and the genes that are 
known to be located in those particular regions. Genes that are associated with leukemia 
or known to be involved in hematopoiesis are shown in bold. 
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Figure 2.1: Frequency of GEMM progenitor cells and in silico mapping. A: GEMM 
progenitor cell frequency as measured by CFC assays. Results are shown as 
colonies/1000 cells seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping 
results when phenotypic information from part A was compared with genotypic 
information based on SNP information for the various inbred mouse strains. Results are 
shown as a -logp value. Circles point out peaks with a -logp value above 2.5. 
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Table 2.1: Genes of interest in regulating GEMM frequency 
Genes located in chromosomal region with –logp values above 2.8 
Gene Region -logp value 
Ptprg, protein tyrosine phosphatase, receptor type, G 14: 12608073-12623845 4.309804 
Cadps, Ca2+-dependent secretion activator 14: 13451373-13528685 4 
Fhit, fragile histidine triad gene 14: 10693745-10736604 3.946922 
Rthyd3, resistance to thymic deletion 3 14: 13387864-13423496 3.928118 
n-R5s45, nuclear encoded rRNA 5S 45 14: 13196426-13337728 3.850781 
Synpr, synaptoporin 14: 14291097-14489374 3.793175 
Atxn7, ataxin 7 14: 14725638-15083409 3.777284 
Olfr720, olfactory receptor 720 14: 14725638-15083409 3.777284 
Psmd6, proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 6 14: 14725638-15083409 3.777284 
Thoc7, THO complex 7 homolog (Drosophila) 14: 14725638-15083409 3.777284 
Rpl19-ps4, ribosomal protein L19, pseudogene 4 14: 14552540-14662129 3.725843 
Sntn, sentan, cilia apical structure protein 14: 14290630-15106086 3.671621 
Fezf2, Fez family zinc finger 2 14: 13174979-13450378 3.659556 
Lrrc3b, leucine rich repeat containing 3B 14: 16103926-16294228 3.518558 
Ngly1, N-glycanase 1 14: 17064860-17090557 3.497573 
Oxsm, 3-oxoacyl-ACP synthase, mitochondrial 14: 17064860-17090557 3.497573 
Rpl21-ps4, ribosomal protein L21, pseudogene 4 14: 12042049-12260227 3.469801 
Iglon5, IgLON family member 5 7: 50735869-50778325 3.354578 
Arhgap24, Rho GTPase activating protein 24 5: 102870089-102911460 3.321482 
Tmc1m4, Tmc1 modifier 4 5: 102870089-102911460 3.321482 
Appd2, APP associated premature death 2 14: 17434991-17778674 3.254926 
Rpl31-ps3, ribosomal protein L31, pseudogene 3 14: 11970057-12401283 3.219683 
Olfr721-ps1, olfactory receptor 721, pseudogene 1 14: 15224397-15419224 3.192465 
Olfr31, olfactory receptor 31 14: 14162704-15177633 3.162412 
Rarb, retinoic acid receptor, beta 14: 17260939-17434727 3.109579 
Top2b, topoisomerase (DNA) II beta 14: 17260939-17434727 3.109579 
Wbcq6, white blood cell quantitative locus 6 14: 17260939-17434727 3.109579 
Nek10, NIMA (never in mitosis gene a)- related kinase 10 14: 15683725-15737034 3.084601 
n-R5s44, nuclear encoded rRNA 5S 44 14: 9779720-9981564 3.059484 
Il3ra, interleukin 3 receptor, alpha chain 14: 13985651-15492174 3.024569 
Slc4a7, solute carrier family 4, sodium bicarbonate 
cotransporter, member 7 14: 11799713-15618059 2.995591 
Evi5, ecotropic viral integration site 5 5: 108163334-108178591 2.818136 
Genes located in chromosomal region with –logp values above 2.5 
Gene Region -logp value 
Ep400, E1A binding protein p400 5: 111108675-111133204 2.759341 
Ptpn13, protein tyrosine phosphatase, non-receptor type 
13 5: 103855361-103866161 2.71364 
Idd21.1, insulin dependent diabetes susceptibility 21.1 18: 78923250-78937776 2.630284 
Bmd8, bone mineral density 8 6: 80953210-80967127 2.614961 
Efw, epididymal fat weight 6: 80953210-80967127 2.614961 
Klhl8, kelch-like 8 (Drosophila) 5: 104324701-104326563 2.600348 
Bmd39, bone mineral density 39 8: 118356974-118360978 2.582694 
Tpi-rs9, triosephosphate isomerase related sequence 9 14: 10871174-18415403 2.569667 
Ascc2, activating signal cointegrator 1 complex subunit 2 14: 9997616-18431455 2.548268 
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The top region (-logp value of 4.3), located in chromosome 14, has a size of 
15.8kbp. It contains protein tyrosine phosphatase, receptor type g (Ptprg), a known tumor 
suppressor gene in mice and humans [22]. It is regulated by estrogen signaling and is 
associated with control of peak bone mineral density in mice [23, 24]. The second region 
(-logp value of 4.0), also located in chromosome 14, is 77.31kbp, and contains the gene 
calcium2+-dependent secretion activator (Cadps). This gene’s expression is associated 
with neuroendocrine tumors called pheochromocytomas, which may be malignant [25]. 
Cadps also has known function in controlling stability and recruitment of insulin granules 
[26]. A third peak (-logp value of 3.9) also located in chromosome 14 spans 42.86kbp 
and contains the fragile histidine triad gene (Fhit). This gene is a known tumor 
suppressor with an aphidicolin-inducible fragile site (FRA3B) known for deletions that 
are frequently observed in de novo acute leukemias [27]. Fhit is associated with type 2 
diabetes and has been shown to inhibit prostaglandin E2 mediated cancer progression 
[28, 29]. 
 
IL-3R genotyping as validation of technique 
 To validate the accuracy of our in silico mapping techniques, the region 
containing interleukin 3 receptor alpha (IL-3R) presented as a significant region with a  
-logp value of 3.02. This region was to serve as a positive control as it presented as a 
region of interest in previous experiments in our laboratory. It is known to have a deletion 
that eliminates the consensus sequence of branch points for RNA splicing [15].This 
deletion causes aberrant splicing of IL-3R, which results in the production of a shorter 
form of IL-3RThis form is not transported to the cell surface and therefore does not 
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mediate actions of IL-3. In multiple strains of mice, this form of IL-3Ra, which contains 
the 5bp deletion, reduces progenitor cell frequency [15]. We evaluated IL-3R in the 27 
mouse strains for genotype based on a previously published method (Fig.2.2) [15]. IL-
3R can have two forms in mice. The A-type mice have a 5bp deletion, whereas the B-
type mice do not. These genotypes were determined by PCR amplification of the region 
of IL-3R including intron 7, which is the location of the branch-point deletion, followed 
by DdeI endonuclease digestion to analyze A and B-type genes. DdeI cuts twice in the 
wild-type intron 7 mice (type B) and only once in mutant intron 7 with the 5bp deletion 
(type A). We compared this genotypic information to the phenotypic order (highest 
progenitor cell frequency to lowest progenitor cell frequency) for the GEMM phenotype 
(Table 2.2). The genotypic form A is found only in strains with low progenitor cell 
frequencies. This finding is consistent with the idea that the A type of IL-3R is involved 
in contributing to low progenitor cell frequency, and therefore served as a proper control 
for our study. There are some strains with low progenitor cell frequency that are B-type 
mice as well. This was anticipated as myeloid progenitor cell frequency is a complex 
trait. A Mann Whitney test (using SigmaPlot) was performed on genotypes A and B. A 
and B types of IL-3R were significantly different with a p-value of 0.0028. 
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Figure 2.2: Genotype of IL-3R in mice. A. Type A has a 5bp deletion previously 
shown to be associated with low progenitor cell frequency. DdeI restriction enzyme 
digestion results in 2 bands for Type A and 3 bands for Type B IL-3R. B. Mouse liver 
DNA was amplified using primers specific to IL-3Ra. PCR products were then digested 
with DdeI and run on a 2% agarose gel to determine genotype. Asterisks denote type A 
strains. A Mann Whitney test (using SigmaPlot) was performed on genotypes A and B.  
A and B types of IL-3R were significantly different with a p-value of 0.0028. 
 
Table 2.2: Comparison of GEMM phenotype and IL-3Ra genotype 
Comparison of GEMM Phenotype and IL-3Ra 
Genotype 
Strain GEMM Progenitor Cell Frequency 
(Colonies/1000 Cells Seeded) 
Genotype 
LP/J 0.448718 B 
C57BLKS/J 0.363446 B 
DBA/2J 0.360417 B 
NZW/lacJ 0.306467 B 
PL/J 0.288063 B 
CBA/J 0.273611 B 
C57BR/cdJ 0.230556 B 
DBA/1J 0.220212 B 
C3H/HeJ 0.188523 B 
C57BL/10J 0.152206 B 
FVB/NJ 0.130556 B 
C57BL/6J 0.114978 B 
129S1/SvImJ 0.079167 B 
SEA/GnJ 0.077083 B 
C57L/J 0.069031 B 
PERA/EiJ 0.068524 B 
C58/J 0.034921 A 
SM/J 0.034722 A 
MA/MyJ 0.032044 B 
A/J 0.03197 A 
BALB/cJ 0.029405 B 
NZB/BINJ 0.024889 A 
I/LnJ 0.02375 A 
WSB/EiJ 0.022991 B 
BALB/cByJ 0.016964 B 
BTBRT+tf/J 0.011111 A 
AKR/J 0.005 A 
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Middle-stage progenitor frequency and in silico mapping 
 A middle-stage progenitor type evaluated was the GM progenitor. This phenotype 
varied among inbred mouse strains, with a range of 0-0.378 colonies/1000 cells seeded 
and greater than a 147-fold difference in the strain with the highest progenitor cell 
frequency and the strain with the lowest progenitor frequency (Fig.2.3A). In silico 
mapping revealed one region with a -logp value above 2.8 and multiple regions with a -
logp value above 2.5.  In silico mapping results using SNPster software are shown in 
Figure 2.3B. Regions in chromosomes 14 and 15 were of genome wide significance after 
correcting for multiple comparisons using EMMA analysis. Table 2.3 shows 
chromosomal regions with -logp values above 2.5, and the genes that are known to be 
located in those particular regions. Genes that are associated with leukemia or known to 
be involved in hematopoiesis are shown in bold.  
 The top region for this phenotype spans 27.42kbp in chromosome 14 and contains 
4 known genes: atherosclerosis 13 (Ath13), cocaine seizure 2 (Cosz2), plasma plant sterol 
1 (plast1), and plasma plant sterol 1b (Plast1b). Ath13 is a gene found in an 
atherosclerosis predisposition study using in silico QTL mapping [30].  Plant sterols 
occur naturally in small quantities in vegetable oils and are also available as food 
additives as they have cholesterol lowering properties [31]. In a genome wide association 
study, Cosz2 was found to be associated with cocaine induced seizure thresholds [32]. 
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Figure 2.3: Frequency of GM progenitor cells and in silico mapping. A: GM 
progenitor cell frequency as measured by CFC assays. Results are shown as 
colonies/1000 cells seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping 
results when phenotypic information from part A was compared with genotypic 
information based on SNP information for the various inbred mouse strains. Results are 
shown as a -logp value. Circles point out peaks with a -logp value above 2.5. 
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Table 2.3: Genes of interest in regulating GM frequency 
Genes located in chromosomal region with –logp values above 2.8 
Gene Region -logp value 
Ath13, atherosclerosis 13 14: 63145626-63173054 2.889386 
Cosz2, cocaine seizure 2 14: 63145626-63173054 2.889386 
Plast1, plasma plant sterol 1 14: 63145626-63173054 2.889386 
Plast1b, plasma plant sterol 1b 14: 63145626-63173054 2.889386 
Genes located in chromosomal region with –logp values above 2.5 
Gene Region -logp value 
Fbxl7, F-box and leucine-rich repeat protein 7 15: 26533596-26539153 2.705725 
Defb43, defensin beta 43 14: 63614409-63639344 2.678805 
Defb47, defensin beta 47 14: 63614409-63639344 2.678805 
 
Late-stage progenitor frequency and in silico mapping 
 The late stage progenitor phenotypes (E, G, and M) varied among inbred mouse 
strains, with ranges of 0.157-0.831, 0.190-0.653, and 0.239-1.055 cells/1000 cells seeded, 
respectively (Fig. 2.4A, 2.5A, and 2.6A). Fold differences in the strain with the highest 
progenitor cell frequency and the strain with the lowest progenitor frequency were 5.3-
fold in E, 3.4-fold in G, and 4.4-fold in M phenotypes. In silico mapping revealed 
multiple regions in each with -logp values above 2.5. In silico mapping results using 
SNPster software are shown in Figure 2.4B, 2.5B, and 2.6B. Tables 2.4, 2.5, and 2.6 
show chromosomal regions with -logp values above 2.5, and the genes that are known to 
be located in those particular regions. Genes that are associated with leukemia or known 
to be involved in hematopoiesis are shown in bold. 
 The top region for E progenitor cell frequency is a 46.23kbp gene in chromosome 
5 containing serine/threonine kinase 32b (Stk32b). This gene is associated with the 
skeletal dysplasias of Ellis-van Creveld syndrome and Weyers acrodental dysostosis [33]. 
The top region for G progenitors is a 26.31kbp region in chromosome 11 containing the 
genes, calcium/calmodulin-dependent protein kinase II beta (Camk2b) and YTK6 
homolog (Ykt6). Group VIA phospholipase A2 forms a signaling complex with Camk2b 
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expressed in pancreatic islet beta-cells. This complex participates in insulin secretion. 
Their expression is co-induced upon differentiation of pancreatic progenitor to endocrine 
progenitor cells [34]. Ytk6 has been associated with tumor invasion and metastasis [35]. 
It is also known to mediate protein palmitoylation, the covalent attachment of FAs to 
cysteine residues of membrane proteins [36]. Another region of significance for this 
phenotype is a 6kbp region located in Chromosome 8. It contains the genes bone mineral 
density 39 (Bmd39) and tetratricopeptide repeat domain 29 (Ttc29). Bmd39 contributes 
to the degree to which bone tissues respond to mechanical loading [37]. Little is known 
about Ttc29. The top region for M progenitors contains the gene Fhit, discussed above. 
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Figure 2.4: Frequency of E progenitor cells and in silico mapping. A: E progenitor 
cell frequency as measured by CFC assays. Results are shown as colonies/1000 cells 
seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping results when 
phenotypic information from part A was compared with genotypic information based on 
SNP information for the various inbred mouse strains. Results are shown as a -logp value. 
Circles point out peaks with a -logp value above 2.5. 
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Table 2.4: Genes of interest in regulating E frequency 
Genes located in chromosomal region with –logp values above 2.8 
Gene Region -logp value 
Stk32b, serine/threonine kinase 32B 5: 38038420-38084656 2.849933 
Genes located in chromosomal region with –logp values above 2.5 
Gene Region -logp value 
Ity2a, immunity to S. typhimurium 2a 11: 52093205-52150216 2.79202 
Tcf7, transcription factor 7, T-cell specific 11: 52093205-52150216 2.79202 
W6q3, weight 6 weeks QTL 3 11: 52093205-52150216 2.79202 
Alpq3, alcohol preference QTL 3 9: 42048114-42065818 2.728445 
Sc5d, sterol-C5-desaturase (fungal ERG3, delta-5-
desaturase) homolog (S. cerevisiae) 
9: 42048114-42065818 2.728445 
Crmp1, collapsin response mediator protein 1 5: 37681204-37711624 2.690689 
Evc, Ellis van Creveld gene homolog (human) 5: 37681204-37711624 2.690689 
Blmpf2, bleomycin-induced pulmonary fibrosis 2 11: 54038026-54056774 2.532897 
Cia40, collagen induced arthritis 40 11: 54038026-54056774 2.532897 
Ckdbp2, chronic kidney disease blood pressure locus 2 11: 54038026-54056774 2.532897 
Pregq1, pregnancy QTL 1 11: 54038026-54056774 2.532897 
Elnv, epilepsy naïve 9: 34385442-34401249 2.527766 
Igan3, IgA nephropathy 3 9: 34385442-34401249 2.527766 
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Figure 2.5: Frequency of G progenitor cells and in silico mapping. A: G progenitor 
cell frequency as measured by CFC assays. Results are shown as colonies/1000 cells 
seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping results when 
phenotypic information from part A was compared with genotypic information based on 
SNP information for the various inbred mouse strains. Results are shown as a -logp value. 
Circles point out peaks with a -logp value above 2.5. 
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Table 2.5: Genes of interest in regulating G frequency 
Genes located in chromosomal region with -logp values above 2.8 
Gene Region -logp value 
Camk2b, calcium/calmodulin-dependent protein 
kinase II,  11: 5864894-5891207 2.815092 
Ykt6, YKT6 homolog (S. Cerevisiae) 11: 5864894-5891207 2.815092 
Bmd39, bone mineral density 39 8: 80875682-80881683 2.801206 
Ttc29, tetratricopeptide repeat domain 29 8: 80875682-80881683 2.801206 
Genes located in chromosomal region with -logp values above 2.5 
Gene Region -logp value 
Erbb2ip, Erbb2 interacting protein 13: 104665228-104684576 2.794302 
Tbqt5, tibia bone quality traits 5 13: 104665228-104684576 2.794302 
Nln, neurolysin (metallopeptidase M3 family) 13: 104701994-104824890 2.694254 
Srsf12, serine/arginine-rich splicing factor 12 13: 104528844-104542789 2.686086 
Pou4f2, POU domain, class 4, transcription factor 2 8: 80947042-81014484 2.613413 
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Figure 2.6: Frequency of M progenitor cells and in silico mapping. A: M progenitor 
cell frequency as measured by CFC assays. Results are shown as colonies/1000 cells 
seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping results when 
phenotypic information from part A was compared with genotypic information based on 
SNP information for the various inbred mouse strains. Results are shown as a -logp value. 
Circles point out peaks with a -logp value above 2.5. 
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Table 2.6: Genes of interest in regulating M frequency 
Genes located in chromosomal region with –logp values above 2.8 
Gene Region -logp value 
Fhit, fragile histidine triad gene 14: 11584520-11656529 2.94897 
Genes located in chromosomal region with –logp values above 2.5 
Gene Region -logp value 
Ctrq2, C. trachomatis resistance QTL 2 3: 131789521-131823292 2.714458 
Dkk2, dickkopf homolog 2 (Xenopus laevis) 3: 131789521-131823292 2.714458 
Dym, dymeclin 18: 75266222-75267209 2.693152 
Idd21.1, insulin dependent diabetes susceptibility 21.1 18: 75266222-75267209 2.693152 
Pgis1, proteoglycan induced spondylitis 1 18: 75266222-75267209 2.693152 
Bmd4, bone mineral density 4 15: 56618365-56626586 2.660179 
Mob5, multigenic obesity 5 2: 110016970-110020628 2.655399 
Plast2b, plasma plant sterol 2b 2: 110016970-110020628 2.655399 
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice 2: 110016970-110020628 2.655399 
Tmc1m1, Tmc1 modifier 1 2: 110016970-110020628 2.655399 
Dclre1a, DNA cross-link repair 1A, PSO2 homolog (S. 
cerevisiae) 19: 56596851-56621288 2.587244 
Rpl21-ps4, ribosomal protein L21, pseudogene 4 14: 12042049-12162496 2.564197 
Slit3, slit homolog 3 (Drosophila) 11: 35100995-35120899 2.520235 
W6q3, weight 6 weeks QTL 3 11: 35100995-35120899 2.520235 
 
 
Total progenitor frequency and in silico mapping 
 Total progenitor cell frequency varied among strains with a range of 0.855-2.933 
colonies/1000 cells seeded and a 3.4 fold difference in the strain with the highest 
progenitor cell frequency and the strain with the lowest progenitor frequency (Fig.2.7A). 
In silico mapping results using SNPster software are shown in Figure 2.7B. Table 2.7 
shows genes within regions that have -logp values above 2.5. Genes that are associated 
with leukemia or known to be involved in hematopoiesis are shown in bold. Fhit and 
Ptprg (genes found in regions of significance in other phenotypes) were located in the top 
chromosomal regions for this phenotype. 
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Figure 2.7: Frequency of total myeloid progenitor cells and in silico mapping. A: 
Total progenitor cell frequency as measured by CFC assays. Results are shown as 
colonies/1000 cells seeded. Error bars represent SEMs (n = 3-5). B: In silico mapping 
results when phenotypic information from part A was compared with genotypic 
information based on SNP information for the various inbred mouse strains. Results are 
shown as a -logp value. Circles point out peaks with a -logp value above 2.5. 
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Table 2.7: Genes of interest in regulating total progenitor cell frequency 
Genes located in chromosomal region with –logp values above 2.5 
Gene Region -logp value 
Fhit, fragile histidine triad gene 14: 11584520-11656342 2.790107 
Ptprg, protein tyrosine phosphatase, receptor type, G 14: 12838623-12859093 2.629132 
Slit3, slit homolog 3 (Drosophila) 11: 35100995-35120899 2.622682 
W6q3, weight 6 weeks QTL 3 11: 35100995-35120899 2.622682 
n-R5s44, nuclear encoded rRNA 5S 44 14: 9797430-9881986 2.509633 
 
IPA and literature searches reveal patterns among genes 
 In addition to confirming our results with the IL-3 R control, we performed a 
meta-analysis of our data by entering the top 50-55 genes (as determined by 
chromosomal region with the highest -logp values) for each phenotype into Ingenuity 
Pathways Analysis (IPA) software. We used IPA to investigate the involvement of 
signaling networks in the regulation of hematopoiesis to determine if there were patterns 
of involvement in biological processes among these genes. Results indicate overlap of 
signaling pathways throughout hematopoiesis, but also show that particular progenitor 
types have genes working in pathways that are specific to their development. A summary 
of this analysis can be found in Table 2.8. Top signaling pathways include cancer, 
hematological disease, metabolism, development, cell cycle, cell growth and 
proliferation, and cell death among others. As top signaling pathways include cancer, 
hematological disease, genetic disorder, and many cancer related processes, this finding 
further supports that our method can be used to identify potential tumor suppressors and 
oncogenes in the regulation of hematopoiesis.  
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Table 2.8: Top IPA signaling pathway for each phenotype. 
IPA Top Signaling Networks 
Phenotype Signaling 
Network 1 
Signaling 
Network 2 
Signaling 
Network 3 
Signaling 
Network 4 
Signaling 
Network 5 
Total Cell Cycle, 
Cardiovascular 
System 
Development 
and Function, 
Cellular 
Development 
 Behavior, 
Cardiovascular 
Disease, 
Cardiovascular 
System 
Development 
and Function 
Cellular 
Development, 
Cellular Growth 
and Proliferation 
  
GEMM Gene 
Expression, 
Cancer, 
Hematological 
Disease 
Cell Death, 
Cell-To-Cell 
Signaling and 
Interaction, 
Cellular 
Growth and 
Proliferation 
RNA Post-
transcriptional 
Modification, 
Nervous System 
Development and 
Function, 
Skeletal and 
Muscular System 
Development and 
Function 
Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
Nucleic Acid 
Metabolism 
Cellular 
Assembly and 
Organization, 
Cellular 
Compromise, 
DNA 
Replication 
Recombination 
and Repair 
GM Cancer, 
Reproductive 
System Disease, 
Tumor 
Morphology 
Lipid 
Metabolism, 
Carbohydrate 
Metabolism, 
Small 
Molecule 
Biochemistry 
Amino Acid 
Metabolism, 
Small Molecule 
Biochemistry, 
Cell Death 
Cancer, 
Cardiovascular 
System 
Development 
and Function, 
Cell Cycle 
 
E Endocrine 
System 
Disorders, 
Genetic 
Disorder, 
Metabolic 
Disease 
Cellular 
Development, 
Hematological 
Disease, 
Immunologica
l Disease 
Developmental 
Disorder, Genetic 
Disorder, 
Embryonic 
Development 
Cancer, 
Cardiovascular 
Disease, 
Cardiovascular 
System 
Development 
and Function 
Genetic 
Disorder , 
Metabolic 
Disease, 
Connective 
Tissue 
Development 
and Function 
G Lipid 
Metabolism, 
Molecular 
Transport, 
Small Molecule 
Biochemistry 
Carbohydrate 
Metabolism, 
Small 
Molecule 
Biochemistry, 
Drug 
Metabolism 
Cancer, 
Reproductive 
System, Genetic 
Disorder 
Cardiovascular 
System 
Development 
and Function, 
Skeletal and 
Muscular 
System 
Development 
and Function, 
Cell 
Morphology 
 
M Cell 
Morphology, 
Neurological 
Disease, Cell 
Cycle 
Cellular 
Compromise, 
Carbohydrate 
Metabolism, 
Molecular 
Transport 
Organismal  
Injury and 
Abnormalities, 
Genetic Disorder, 
Hepatic System 
Disease 
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 As IPA was limited in recognizing genes that relatively little is known about in 
signaling pathways, we also conducted literature searches using PubMed to understand 
more about the patterns among these top genes. For example, bone mineral density genes, 
bone quality genes, and many genes related to other bone properties are not recognized in 
signaling pathways in IPA, yet they make up 18% of the genes in our meta-analysis. 
Results for these literature searches can be found in Table 2.9. In the literature searches 
conducted, we found that 11% of genes in our listing for the top 50 genes in each 
phenotype are known to be associated with the regulation of hematopoiesis. Thirty 
percent of genes are known to be associated with cancer. Of these, there seems to be a 
mix of genes related to many cancer processes and types. As progenitor cell frequency is 
related to AML and its precursors, it is not surprising that 15% of genes returned on the 
top genes lists are previously known to be involved in leukemias specifically. Taken 
together, these data also support our use of these techniques to identify tumor suppressors 
and oncogenes in hematopoietic regulation. In addition, 18% of the top genes are 
involved in bone properties, 20% are related to FA, fat, or atherosclerosis, and 19% are 
related to insulin or diabetes. Of the genes in these top genes lists, several have been 
shown to be involved in regulating hematopoiesis or contributing to leukemia (shown in 
bold), whereas most are novel candidate genes for these processes. 
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Table 2.9: Genes located in regions with highest -logp values associated with 
relevant processes/qualities.  
Genes located in regions with highest -logp values associated with relevant 
processes/qualities 
Cancer (30%) 
Cadps, Top2b, Rarb, Ep400, Ptpn13, Net1, Ikbkap, Skts-fp1, Fbxl7, Ints6, 
Ctsb, Scara5, Msra, Gata4, Pou6f1, Blk, Dleu2, Kcnrg, Mir15a, Mir16-1, 
Trim13, Elp3, Neil2, Tdh, Tcf7, Crmp1, Ptprt, Cbx5, Smug1, Slc22a4, 
Cinda3, Stx18, Flt1, Slit3, Ykt6, Erbb2ip, Nln, Mpped2, Opcml, Rgs4, 
Adamts6, Slc13a1, Hcn1, Dkk2, Dym, Afap1l2, ,Vwa2, Lrrk2, Slc2a13, 
Myo5b, Dcc, Casp7, Fat1, Mtnr1a, Lama1, Ptprg, Evi5, Nek10, Slc4a7, 
Sntn, Wasl, Fhit, Lrrc3b, Psmd6    
Leukemia (15%) 
Il3ra, Ptpn13, Gata4, Blk, Dleu2, Mir15a, Mir16-1, Trim13, Tcf7, Cbx5, 
Slc22a4, Flt1, Rgs4, Dcc, Casp7, Evi5, Wasl, Fhit, Rarb, Top2b, Net1, 
Ctsb, Kcnrg, Crmp1, Ptprt, Erbb2ip, Slc13a1, Lrrk2, Lama1, Lrrc3b, 
Arhgap24, Camk2b, F11 
Hematopoiesis (11%) 
Il3ra, Ep400, Ptpn13, Gata4, Blk, Dleu2, Mir15a, Mir16-1, Trim13, Tcf7, 
Cbx5, Slc22a4, Flt1, Rgs4, Dcc, Casp7, Evi5, Wasl, Fhit, Jakmip1, Ptprg, 
Rarb, Wbcq6 
Bone Properties (18%) 
Slc22a4, Rgs4, Dcc, Casp7, Wasl, Fhit, Slc13a1, Lama1, Dkk2, Dym, 
Bmd8, Bmd39, Bmd3, Bmch2, Bmd4, Bmd5, Bmd7, Evc2, Tbqt5, Bmd1, 
Evc, Pgis1, Ptprg, Mir199a-1, Tcf7, Blk, Rarb, Stk32b, Il3ra, Net1, Ctsb, 
Agnm2, Bdlnq7, Flt1, Fezf2, Pou4f2, Gata4, Dcdc5, Ptpn13 
Fatty acid, Fat, or 
Atherosclerosis (20%) 
Slc22a4, Rgs4, Dcc, Casp7, Wasl, Fhit, Ptprg, Blk, Rarb, Il3ra, Ctsb, Flt1, 
Gata4, Erbb2ip, Camk2b, F11, Ikbkap, Msra, Tdh, Ykt6, Hcn1, Fat1, 
Oxsm, Plast1, Plast1b, Lmbrd1, Sc5d, Plast2b, Tcf7, Dleu2, Ptprt, Myo5b, 
Mtnr1a, Efw, Mob5, T2dm2sa,  Dkk2, Bmd8, Scara5, Ath8, Ath13, Mtmr9, 
Xkr6, Dnm2, Ascc2 
Insulin or Diabetes (19%) 
Slc22a4, Rgs4, Dcc, Casp7, Wasl, Blk, Ctsb, Flt1, Gata4, F11, Ikbkap, 
Msra, Plast1, Plast1b, Tcf7, Dleu2, Myo5b, Mtnr1a, Efw, Mob5, T2dm2sa, 
Fhit, Camk2b, Tdh, Hcn1, Lama1, Crmp1, Pou4f2, Ptpn13, Cadps, Ints6, 
Pou6f1, Vwa2, Idd21.1, Fam167a, Ap2a1, Idd26, Athsq1, Bglu1, Aod2, 
Idd21.2 
 
Discussion 
 The strength of in silico mapping method over more traditional methods is evident 
as it provides denser marker sets and makes comparisons that are based on regions of the 
genome inherited from common ancestors, as opposed to traditional quantitative trait loci 
(QTL) studies that rely only on loci inherited from different progenitors. Comparison 
across a greater number of strains also provides greater statistical power. This type of 
haplotype associated mapping has successfully proven to be more powerful in narrowing 
chromosomal regions of interest than traditional QTL mapping in multiple studies [38, 
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39]. This method has been confirmed to identify chromosomal regions containing genes 
that are known to be associated with the particular phenotype [19]. This was evident in 
our study as well, as the region of chromosome 14 containing IL-3R presented with a 
high -logp value. The region containing IL-3R was a control for our study. IL-3Ris 
mutated in multiple inbred mouse strains causing their progenitor cell frequencies to be 
reduced.  
 Our results pointed to regions identified in previous QTL studies, while providing 
greater resolution. Henckaerts et al. [40] found that the following QTLs are of importance 
to the hematopoietic progenitor cell compartment: chromosome 4(37.6-48.5 and 66-
78.5cM), chromosome 2(72.1-77.2cM), chromosome 9(23-27cM), and chromosome 14 
(broad range). We found that chromosome 4(42.13-45.76cM) contains genes that overlap 
with the previous QTL study. These genes are autoimmune glomerulonephritis in MRL 2 
(Agnm2) and bone mineral density (Bmd7). They are contained within a region important 
to granulocyte progenitor cell frequency. Chromosome 4(74.75-75.77cM) contains the 
overlapping genes of atherosclerosis susceptibility QTL 1(Athsq1), cytokine induced 
activation 3(Cinda3), and forkhead-associated phosphopeptide binding domain 1 
(Fhad1), in a region that is important to progenitor cell frequency in erythrocyte, and 
total frequency phenotypes.  Chromosome 2(80.93-85.27) contains one overlapping gene, 
spontaneous crescentic glomerulonephritis QTL 3(Scgq3). Chromosome 9(23.57cM) 
contains the overlapping gene, sterol-C5-desaturase (Sc5d), in a region that is important 
to erythrocyte development. We also found several very significant regions within 
chromosome 14. Henckaerts et al. [41] also found that a region of chromosome 2 is 
important to stem and progenitor cell populations. They found that the region at 73.2-
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77.2cM in chromosome 2 is a QTL for early hematopoietic populations. We found a 
region of chromosome 2 at 80.92-80.96cM that contains genes that overlap the previously 
discovered QTL. Another group found that a QTL at chromosome 2 regulates stem cell 
numbers in the bone marrow [42]. Interestingly, the gene alcohol preference QTL 1 
(Alpq1) was located in this region. Our studies resulted in a region of chromosome 
9(20.76cM) containing alcohol preference QTL 3 (Alpq3). These were both identified in 
genome wide association studies for alcohol preference [43]. Chronic alcohol use induces 
bone loss through the suppression of Wnt signaling [44]. 
 Additionally, a portion of mouse chromosome 11 that presented in the E 
progenitor phenotype from our study corresponds to human chromosome 5, specifically 
region 5q31.1. This particular region of chromosome 5 undergoes deletion in 5q- 
syndrome, which is a disorder that affects bone marrow cells and causes severe 
macrocytic anemia and myelodysplastic syndromes that may lead to AML. It is 
characterized by a defect in erythroid differentiation and is often accompanied by 
erythroid hypoplasia in the bone marrow [45]. It is fitting that this region presented in the 
E progenitor phenotype. This result further validates our methods. Genes contained in the 
region are transcription factor 7 (Tcf7), CDC42 small effector 2 (Cdc42se2), follistatin-
like 4 (Fstl4), Rap guanine nucleotide exchange factor 6 (Rapgef6), and solute carrier 
family 22 member 4 (Slc22a4).  
 Our meta-analysis of the top 50-55 genes within the chromosomal regions with 
the highest -logp values for each phenotype revealed interesting patterns. Overall, there 
were 39 genes associated with bone mineral density, bone quality, bone mechanics, and 
bone disease. These genes are located in several different chromosomal regions. Seven of 
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these were bone mineral density genes: Bmd1, Bmd3, Bmd4, Bmd5, Bmd7, Bmd8, and 
Bmd39. Bone mechanical trait 2 (Bmch2) also showed up in our meta-analysis as well as 
tibia bone quality trait 5 (Tbqt5). Several additional genes were involved in osteogenesis, 
skeletal formation, bone morphogenic signaling, osteoclast differentiation, osteoblast 
differentiation, skeletal size, bone growth plate regulation, and bone disease [46-55]. This 
finding suggests a role of bone properties in determining how myeloid cells develop. 
Additional support for the idea of bone properties being key regulators of myeloid 
progenitor cell frequency lies in the high number of genes related to calcium and estradiol 
signaling that were located in chromosomal regions of high -logp values as well. The 
roles of calcium and estradiol in the quality of bone have been well documented. [56-62]  
 Another interesting pattern involved metabolism. Twenty percent of the genes 
returned in our analysis were related to FA uptake and oxidation, lipid metabolism, and 
atherosclerosis susceptibility [63-70]. This finding supports our previous work that shows 
that the ratio of omega 3 to omega 6 FAs in the diet has a significant effect on progenitor 
cell frequency in the bone marrow of mice [11]. Furthermore, these qualities have been 
shown to regulate bone mineral density in humans and mice. High fat diets lower bone 
mineral density and bone volume [69, 61]. One study also correlates QTLs for body size 
(body weight, length, and adipose mass) with those identified for skeletal traits, 
suggesting that many QTLs may regulate bone properties via their effect on body size 
[72]. 
 Genes associated with glucose metabolism, insulin, and diabetes susceptibility 
were also present in high numbers in our meta-analysis. These genes have been show to 
have a major role in bone remodeling and metabolism. Osteoblasts express insulin 
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receptors and favor glucose metabolism through the hormone osteocalcin. Insulin 
signaling in osteoblasts is necessary for whole-body glucose homeostasis because it 
increases osteocalcin activity.  Osteoclasts can determine the status and function of 
osteocalcin and, accordingly, increase or decrease insulin signaling in osteoblasts. This 
determination then promotes or hampers glucose metabolism in a bone resorption-
dependent manner in mice and humans [73]. As insulin stops the use of fat as an energy 
source, lack of control of insulin levels can have a profound effect on fat stores in the 
body. Insulin’s direct effect on FA synthesis in the body could play a role in the bone 
properties associated with fat as well. Furthermore, insulin receptor interacting proteins 
have been shown to regulate hematopoietic stem and progenitor cell pools [74]. 
 Future directions for our lab include determining if the genes located in these 
chromosomal regions with high -logp values are in fact associated with changes in 
myeloid progenitor cell frequency. In order to complete this work, we will investigate 
these novel candidate genes one by one, beginning with those in which nucleotides 
correlate strongly with phenotypic data and are involved in the processes that our data 
suggest are regulators of hematopoiesis. We will test these genes for function in 
hematopoiesis by altering their expression. We will also determine if the particular 
pathways that emerged the most (bone properties and metabolic processes) are 
biomarkers for AML progression risk. Additionally, we will validate the role of these 
genes and pathways in human hematopoiesis and AML progression. 
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GEMM top genes list 
Gene Region -logp value 
Ptprg, protein tyrosine phosphatase, receptor type, G 14: 12608073-12623845 4.309804 
Cadps, Ca2+-dependent secretion activator 14: 13451373-13528685 4 
Fhit, fragile histidine triad gene 14: 10693745-10736604 3.946922 
Rthyd3, resistance to thymic deletion 3 14: 13387864-13423496 3.928118 
n-R5s45, nuclear encoded rRNA 5S 45 14: 13196426-13337728 3.850781 
Synpr, synaptoporin 14: 14291097-14489374 3.793175 
Atxn7, ataxin 7 14: 14725638-15083409 3.777284 
Olfr720, olfactory receptor 720 14: 14725638-15083409 3.777284 
Psmd6, proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 14: 14725638-15083409 3.777284 
Thoc7, THO complex 7 homolog (Drosophila) 14: 14725638-15083409 3.777284 
Rpl19-ps4, ribosomal protein L19, pseudogene 4 14: 14552540-14662129 3.725843 
Sntn, sentan, cilia apical structure protein 14: 14290630-15106086 3.671621 
Fezf2, Fez family zinc finger 2 14: 13174979-13450378 3.659556 
Lrrc3b, leucine rich repeat containing 3B 14: 16103926-16294228 3.518558 
Ngly1, N-glycanase 1 14: 17064860-17090557 3.497573 
Oxsm, 3-oxoacyl-ACP synthase, mitochondrial 14: 17064860-17090557 3.497573 
Rpl21-ps4, ribosomal protein L21, pseudogene 4 14: 12042049-12260227 3.469801 
Iglon5, IgLON family member 5 7: 50735869-50778325 3.354578 
Arhgap24, Rho GTPase activating protein 24 5: 102870089-102911460 3.321482 
Tmc1m4, Tmc1 modifier 4 5: 102870089-102911460 3.321482 
Appd2, APP associated premature death 2 14: 17434991-17778674 3.254926 
Rpl31-ps3, ribosomal protein L31, pseudogene 3 14: 11970057-12401283 3.219683 
Olfr721-ps1, olfactory receptor 721, pseudogene 1 14: 15224397-15419224 3.192465 
Olfr31, olfactory receptor 31 14: 14162704-15177633 3.162412 
Rarb, retinoic acid receptor, beta 14: 17260939-17434727 3.109579 
Top2b, Topoisomerase (DNA), beta II 14: 17260939-17434727 3.109579 
Wbcq6, white blood cell quantitative locus 6 14: 17260939-17434727 3.109579 
Nek10, NIMA (never in mitosis gene a)- related kinase 10 14: 15683725-15737034 3.084601 
n-R5s44, nuclear encoded rRNA 5S 44 14: 9779720-9981564 3.059484 
Il3ra, interleukin 3 receptor, alpha chain 14: 13985651-15492174 3.024569 
Slc4a7, solute carrier family 4, sodium bicarbonate cotransporter, 
member 7 14: 11799713-15618059 2.995591 
Evi5, ecotropic viral integration site 5 5: 108163334-108178591 2.818136 
Ep400, E1A binding protein p400 5: 111108675-111133204 2.759341 
Ptpn13, protein tyrosine phosphatase, non-receptor type 13 5: 103855361-103866161 2.71364 
Idd21.1, insulin dependent diabetes susceptibility 21.1 18: 78923250-78937776 2.630284 
Bmd8, bone mineral density 8 6: 80953210-80967127 2.614961 
Efw, epididymal fat weight 6: 80953210-80967127 2.614961 
Klhl8, kelch-like 8 (Drosophila) 5: 104324701-104326563 2.600348 
Bmd39, bone mineral density 39 8: 118356974-118360978 2.582694 
Tpi-rs9, triosephosphate isomerase related sequence 9 14: 10871174-18415403 2.569667 
Ascc2, activating signal cointegrator 1 complex subunit 2 14: 9997616-18431455 2.548268 
Caln1, calneuron 1 5: 130890171-130891984 2.488252 
Vmn2r62, vomeronasal 2, receptor 62 7: 50006469-50091657 2.453735 
Bmd3, bone mineral density 3 13: 3190342-3242611 2.450389 
Tyw1, tRNA-yW synthesizing protein 1 homolog (S. cerevisiae) 5: 130758991-130829540 2.431364 
Net1, neuroepithelial cell transforming gene 1 13: 3876452-3899689 2.418577 
Noc4l, nucleolar complex associated 4 homolog (S. cerevisiae) 5: 111079377-111080089 2.409792 
Ath8, atherosclerosis 8 4: 56766913-56778159 2.406824 
Bmch2, bone mechanical trait 2 4: 56766913-56778159 2.406824 
Ctrcts, cataract severity 4: 56766913-56778159 2.406824 
Ikbkap, inhibitor of kappa light polypeptide enhancer in B-cells, kinase 
complex-associated protein 4: 56766913-56778159 2.406824 
Skts-fp1, skin tumor susceptibility in FVB and PWK 1 4: 56766913-56778159 2.406824 
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GM top genes list 
Gene Region -logp value 
Ath13, atherosclerosis 13 14: 63145626-63173054 2.889386 
Cosz2, cocaine seizure 2 14: 63145626-63173054 2.889386 
Plast1, plasma plant sterol 1 14: 63145626-63173054 2.889386 
Plast1b, plasma plant sterol 1b 14: 63145626-63173054 2.889386 
Fbxl7, F-box and leucine-rich repeat protein 7 15: 26533596-26539153 2.705725 
Defb43, defensin beta 43 14: 63614409-63639344 2.678805 
Defb47, defensin beta 47 14: 63614409-63639344 2.678805 
Fam124a, family with sequence similarity 124, member A 14: 63139934-63190101 2.470732 
Atp8a2, ATPase, aminophospholipid transporter-like 14: 60475030-60613198 2.462052 
Ints6, integrator complex subunit 6 14: 63310514-63363750 2.459213 
Serpine3, serpin peptidase inhibitor, member 3 14: 63310514-63363750 2.459213 
Ctsb, cathepsin B 14: 63696395-63747802 2.425771 
Scara5, scavenger receptor class A, member 5 (putative) 14: 66279212-66323155 2.423693 
Fbxo16, F-box protein 16 14: 65923363-66010722 2.420556 
Zfp395, zinc finger protein 395 14: 65923363-66010722 2.420556 
Gucy1b2, guanylate cyclase 1, soluble, beta 2 14: 63073236-63133525 2.408946 
Msra, methionine sulfoxide reductase A 14: 64700581-64935824 2.394743 
Prss51, protease, serine, 51 14: 64700581-64935824 2.394743 
Prss52, protease, serine, 52 14: 64700581-64935824 2.394743 
Prss55, protease, serine, 55 14: 64700581-64935824 2.394743 
Zfp658, zinc finger protein 658 7: 50806886-50879931 2.296665 
Zfp719, zinc finger protein 719 7: 50806886-50879931 2.296665 
Zfp819, zinc finger protein 819 7: 50806886-50879931 2.296665 
Gata4, GATA binding protein 4 14: 63819697-63990229 2.290406 
Bmd4, bone mineral density 4 15: 100386574-100411741 2.286494 
Pou6f1, POU domain, class 6, transcription factor 1 15: 100386574-100411741 2.286494 
Blk, B lymphoid kinase 14: 63813790-64091361 2.254468 
Fam167a, family with sequence similarity 167, member A 14: 63813790-64091361 2.254468 
Dleu2, deleted in lymphocytic leukemia, 2 14: 62190971-62280557 2.233419 
Kcnrg, potassium channel regulator 14: 62190971-62280557 2.233419 
Mir15a, microRNA 15a 14: 62190971-62280557 2.233419 
Mir16-1, microRNA 16-1 14: 62190971-62280557 2.233419 
Trim13, tripartite motif-containing 13 14: 62190971-62280557 2.233419 
Elp3, elongation protein 3 homolog (S. cerevisiae) 14: 66148441-66169246 2.214623 
Kif13b, kinesin family member 13B 14: 65347007-65376483 2.193357 
Arhgap6, Rho GTPase activating protein 6 X: 165319571-165322740 2.180174 
Bmd5, bone mineral density 5 1: 123019155-123039644 2.144574 
Bwq7, body weight, QTL 7 1: 123019155-123039644 2.144574 
Scgq2, spontaneous crescentic glomerulonephritis QTL 2 1: 123019155-123039644 2.144574 
Mtmr9, myotubularin related protein 9 14: 63809198-64260649 2.144055 
Neil2, nei like 2 (E. coli) 14: 63809198-64260649 2.144055 
Tdh, L-threonine dehydrogenase 14: 63809198-64260649 2.144055 
Xkr6, X Kell blood group precursor related family member 6  14: 63809198-64260649 2.144055 
Ap2a1, adaptor protein complex AP-2, alpha 1 subunit 7: 52178097-52178425 2.142233 
Iglon5, IgLON family member 5 7: 50738756-50775032 2.120025 
Cadps, Ca2+-dependent secretion activator 14: 13505483-13522770 2.101804 
Defb30, defensin beta 30 14: 63593927-63750325 2.09575 
Defb42, defensin beta 42 14: 63593927-63750325 2.09575 
Defb48, defensin beta 48 14: 63593927-63750325 2.09575 
Fecq3, fecundity QTL 3 1: 24822648-24829896 2.093422 
Idd26, insulin dependent diabetes susceptibility 26 1: 24822648-24829896 2.093422 
Lmbrd1, LMBR1 domain containing 1 1: 24822648-24829896 2.093422 
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E top genes list 
Gene Region -logp value 
Stk32b, serine/threonine kinase 32B 5: 38038420-38084656 2.849933 
Ity2a, immunity to S. typhimurium 2a 11: 52093205-52150216 2.79202 
Tcf7, transcription factor 7, T-cell specific  11: 52093205-52150216 2.79202 
W6q3, weight 6 weeks QTL 3 11: 52093205-52150216 2.79202 
Alpq3, alcohol preference QTL 3 9: 42048114-42065818 2.728445 
Sc5d, sterol-C5-desaturase  9: 42048114-42065818 2.728445 
Crmp1, collapsin response mediator protein 1 5: 37681204-37711624 2.690689 
Evc, Ellis van Creveld gene homolog (human) 5: 37681204-37711624 2.690689 
Blmpf2, bleomycin-induced pulmonary fibrosis 2 11: 54038026-54056774 2.532897 
Cia40, collagen induced arthritis 40 11: 54038026-54056774 2.532897 
Ckdbp2, chronic kidney disease blood pressure locus 2 11: 54038026-54056774 2.532897 
Pregq1, pregnancy QTL 1 11: 54038026-54056774 2.532897 
Elnv, epilepsy naïve 9: 34385442-34401249 2.527766 
Igan3, IgA nephropathy 3 9: 34385442-34401249 2.527766 
Athsq1, atherosclerosis susceptibility QTL 1 4: 142154832-142171686 2.46515 
Bmd7, bone mineral density 7 4: 142154832-142171686 2.46515 
Cytl1, cytokine-like 1 5: 38104702-38133786 2.435442 
Synj1, synaptojanin 1 16: 90991665-91012590 2.432217 
Bdlnq7, body length QTL 7 2: 160241262-160460912 2.431364 
Bglu1, blood glucose level 1 2: 160241262-160460912 2.431364 
Mob5, multigenic obesity 5 2: 160241262-160460912 2.431364 
Prdt2, prion disease incubation time 2 2: 160241262-160460912 2.431364 
Scgq3, spontaneous crescentic glomerulonephritis QTL 3 2: 160241262-160460912 2.431364 
Cdc42se2, CDC42 small effector 2 11: 54532428-54574973 2.416867 
Fstl4, follistatin-like 4 11: 52789869-52808156 2.368597 
Evc2, Ellis van Creveld syndrome 2 homolog (human) 5: 37676733-37736901 2.344392 
Arsj, arylsulfatase J 3: 126107801-126111371 2.298671 
Ctrq2, C. trachomatis resistance QTL 2 3: 126107801-126111371 2.298671 
Rapgef6, Rap guanine nucleotide exchange factor (GEF) 6 11: 54492977-54520054 2.28537 
Ptprt, protein tyrosine phosphatase, receptor type, T 2: 162384520-162390034 2.284619 
Jakmip1, janus kinase and microtubule interacting protein 1 5: 37515261-37745440 2.280844 
Chd6, chromodomain helicase DNA binding protein 6 2: 160787704-160857202 2.279515 
Fhit, fragile histidine triad gene 14: 10402891-10416373 2.251435 
Bmd4, bone mineral density 4 15: 102961141-103060839 2.251233 
Cbx5, chromobox homolog 5 (Drosophila HP1a) 15: 102961141-103060839 2.251233 
Smug1, single-strand selective monofunctional uracil DNA 
glycosylase 15: 102961141-103060839 2.251233 
Slc22a4, solute carrier family 22, member 4 11: 53799692-53822305 2.250217 
Tbqt5, tibia bone quality traits 5 13: 107080581-107145390 2.241795 
Alan2, alloantigen response 2 4: 141979409-141982891 2.240757 
Cinda3, cytokine induced activation 3 4: 141979409-141982891 2.240757 
Stx18, syntaxin 18 5: 38259984-38490902 2.22981 
Lrrc3b, leucine rich repeat containing 3B 14: 16181610-16207728 2.217484 
Ath13, atherosclerosis 13 14: 101291502-101501656 2.215726 
Plast1, plasma plant sterol 1 14: 101291502-101501656 2.215726 
Plast1b, plasma plant sterol 1b 14: 101291502-101501656 2.215726 
Flt1, FMS-like tyrosine kinase 1 5: 148421156-148422167 2.200029 
Slit3, slit homolog 3 (Drosophila) 11: 35100995-35120899 2.197969 
Ptprg, protein tyrosine phosphatase, receptor type, G 14: 12383660-12401283 2.193588 
Aaom1, autoimmune aoritis in MRL mice 1 4: 141360892-141385435 2.187286 
Pregq4, pregnancy QTL 4 17: 67731385-67741554 2.172943 
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G top genes list 
Gene Region -logp value 
Camk2b, calcium/calmodulin-dependent protein kinase II,  11: 5864894-5891207 2.815092 
Ykt6, YKT6 homolog (S. Cerevisiae) 11: 5864894-5891207 2.815092 
Bmd39, bone mineral density 39 8: 80875682-80881683 2.801206 
Ttc29, tetratricopeptide repeat domain 29 8: 80875682-80881683 2.801206 
Erbb2ip, Erbb2 interacting protein 13: 104665228-104684576 2.794302 
Tbqt5, tibia bone quality traits 5 13: 104665228-104684576 2.794302 
Nln, neurolysin (metallopeptidase M3 family) 13: 104701994-104824890 2.694254 
Srsf12, serine/arginine-rich splicing factor 12 13: 104528844-104542789 2.686086 
Pou4f2, POU domain, class 4, transcription factor 2 8: 80947042-81014484 2.613413 
Bmd3, bone mineral density 3 13:10435947-10438947 2.499005 
Mob5, multigenic obesity 5 2: 106553007-106556649 2.467799 
Mpped2, metallophosphoesterase domain containing 2 2: 106553007-106556649 2.467799 
Plast2b, plasma plant sterol 2b 2: 106553007-106556649 2.467799 
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice 2: 106553007-106556649 2.467799 
Tmc1m1, Tmc1 modifier 1 2: 106553007-106556649 2.467799 
Slc10a7, solute carrier family 10, member 7 8: 81034594-81058787 2.46594 
Rbmxrt, RNA binding motif protein, retrogene 8: 81029162-81029320 2.449382 
Scgq2, spontaneous crescentic glomerulonephritis QTL 2 1: 126683785-126717845 2.332438 
Bmd5, bone mineral density 5 1: 126683785-126717845 2.332438 
Sxbq2, SGC/Knj cross B6 QTL 2 6: 24951661-25113230 2.312636 
Ath13, atherosclerosis 13 14: 58830212-58836142 2.296665 
Cosz2, cocaine seizure 2 14: 58830212-58836142 2.296665 
Plast1, plasma plant sterol 1 14: 58830212-58836142 2.296665 
Plast1b, plasma plant sterol 1b 14: 58830212-58836142 2.296665 
Svtms, survival time modifier of Sod2 13: 117968579-117969103 2.276845 
Opcml, opioid binding protein/cell adhesion molecule-like 9: 27911936-27975158 2.215064 
Bmd1, bone mineral density 1 1: 171619669-171639814 2.206376 
Rgs4, regulator of G-protein signaling 4 1: 171619669-171639814 2.206376 
Scgq1, spontaneous crescentic glomerulonephritis QTL 1 1: 171619669-171639814 2.206376 
Sle16, systematic lupus erythematosus susceptibility 16 1: 171619669-171639814 2.206376 
Adamts6, a disintegrin-like and metallopeptidase  13: 105275519-105288870 2.178497 
Slc13a1, solute carrier family 13, member 1 6: 24067291-24276244 2.158614 
Nacad, NAC alpha domain containing 11: 6501551-6527323 2.138303 
Snora5c, small nucleolar RNA, H/ACA box 5C 11: 6501551-6527323 2.138303 
Tbrg4, transforming growth factor beta regulated gene 4 11: 6501551-6527323 2.138303 
Kcnip1, Kv channel-interacting protein 1 11: 33621650-33649999 2.110309 
W6q3, weight 6 weeks QTL 3 11: 33621650-33649999 2.110309 
Dnm2, dynamin 2 9: 21242462-21309077 2.106644 
Mir199a-1, microRNA 199a-1 9: 21242462-21309077 2.106644 
Hcn1, hyperpolarization-activated, cyclic nucleotide-gated K+ 1 13: 118500852-118528940 2.106644 
Plekha5, pleckstrin homology domain containing, member 5 6: 140330684-140381709 2.105794 
Agnm2, autoimmune glomerulonephritis in MRL 2 4: 118439097-118439315 2.097489 
Anxty, anxiety 4: 118439097-118439315 2.097489 
Bmd7, bone mineral density 7 4: 118439097-118439315 2.097489 
Dcdc5, doublecortin domain containing 5 2: 106132643-106160544 2.080386 
Hyal4, hyaluronoglucosaminidase 4 6: 24597981-24886492 2.051474 
Hyal5, hyaluronoglucosaminidase 5 6: 24597981-24886492 2.051474 
Hyal6, hyaluronoglucosaminidase 6 6: 24597981-24886492 2.051474 
Spam1, sperm adhesion molecule 1 6: 24597981-24886492 2.051474 
Wasl, Wiskott-Aldrich syndrome-like (human) 6: 24597981-24886492 2.051474 
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M top genes list  
Gene Region -logp value 
Fhit, fragile histidine triad gene 14: 11584520-11656529 2.94897 
Ctrq2, C. trachomatis resistance QTL 2 3: 131789521-131823292 2.714458 
Dkk2, dickkopf homolog 2 (Xenopus laevis) 3: 131789521-131823292 2.714458 
Dym, dymeclin 18: 75266222-75267209 2.693152 
Idd21.1, insulin dependent diabetes susceptibility 21.1 18: 75266222-75267209 2.693152 
Pgis1, proteoglycan induced spondylitis 1 18: 75266222-75267209 2.693152 
Bmd4, bone mineral density 4 15: 56618365-56626586 2.660179 
Mob5, multigenic obesity 5 2: 110016970-110020628 2.655399 
Plast2b, plasma plant sterol 2b 2: 110016970-110020628 2.655399 
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice 2: 110016970-110020628 2.655399 
Tmc1m1, Tmc1 modifier 1 2: 110016970-110020628 2.655399 
Dclre1a, DNA cross-link repair 1A, PSO2 homolog (S. cerevisiae) 19: 56596851-56621288 2.587244 
Rpl21-ps4, ribosomal protein L21, pseudogene 4 14: 12042049-12162496 2.564197 
Slit3, slit homolog 3 (Drosophila) 11: 35100995-35120899 2.520235 
W6q3, weight 6 weeks QTL 3 11: 35100995-35120899 2.520235 
Synpr, synaptoporin 14: 14202231-14220929 2.497986 
Ptprg, protein tyrosine phosphatase, receptor type, G 14: 12445127-12526023 2.492895 
Afap1l2, actin filament associated protein 1-like 2 19: 56936971-56992931 2.488735 
Tdrd1, tudor domain containing 1 19: 56936971-56992931 2.488735 
Vwa2, von Willebrand factor A domain containing 2 19: 56936971-56992931 2.488735 
Lrrk2, leucine-rich repeat kinase 2 15: 91386924-91588341 2.478729 
Slc2a13, solute carrier family 2 , member 13 15: 91386924-91588341 2.478729 
Myo5b, myosin VB 18: 74863638-74889684 2.473403 
Cadps, Ca2+-dependent secretion activator 14: 13563270-13578052 2.459644 
Wdr67, WD repeat domain 67 15: 57796753-57816553 2.381197 
Aod2, autoimmune ovarian dysgenesis 2 3: 52458253-52592669 2.37429 
Ath13, atherosclerosis 13 14: 82146864-82154961 2.346516 
Plast1, plasma plant sterol 1 14: 82146864-82154961 2.346516 
Plast1b, plasma plant sterol 1b 14: 82146864-82154961 2.346516 
Lrrc3b, leucine rich repeat containing 3B 14: 16205186-16228725 2.341599 
Appd2, APP associated premature death 2 14: 17434991-17580486 2.290776 
Nhlrc2, NHL repeat containing 2 19: 56570749-56660884 2.285557 
n-R5s44, nuclear encoded rRNA 5S 44 14: 9779720-9874620 2.281791 
Idd21.2, insulin dependent diabetes susceptibility 21.2 14: 14470385-14489374 2.267598 
Gm3614, predicted gene 3614 14: 11969250-12401283 2.257278 
Fezf2, Fez family zinc finger 2 14: 13174979-13196712 2.241588 
Anxty, anxiety 4: 125536444-125587189 2.205249 
Bmd7, bone mineral density 7 4: 125536444-125587189 2.205249 
Ctrcts, cataract severity 4: 125536444-125587189 2.205249 
Eae40, experimental allergic encephalomyelitis 40 4: 125536444-125587189 2.205249 
Dcc, deleted in colorectal carcinoma 18: 72369674-72489317 2.200258 
Dclre1a, DNA cross-link repair 1A, PSO2 homolog  19: 56556474-56716524 2.174883 
Nek10, NIMA (never in mitosis gene a)- related kinase 10 14: 15737733-15748613 2.151523 
Atrnl1, attractin like 1 19: 58171868-58183830 2.133273 
Rthyd3, resistance to thymic deletion 3 14: 13316480-13423496 2.132206 
Casp7, caspase 7 19: 56510580-56536292 2.119476 
Bmd39, bone mineral density 39 8: 46044747-46343089 2.108621 
F11, coagulation factor XI 8: 46044747-46343089 2.108621 
Fat1, FAT tumor suppressor homolog 1 (Drosophila) 8: 46044747-46343089 2.108621 
Mtnr1a, melatonin receptor 1A 8: 46044747-46343089 2.108621 
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Total top genes list 
Gene Region -logp value 
Fhit, fragile histidine triad gene 14: 11584520-11656342 2.790107 
Ptprg, protein tyrosine phosphatase, receptor type, G 14: 12838623-12859093 2.629132 
Slit3, slit homolog 3 (Drosophila) 11: 35100995-35120899 2.622682 
W6q3, weight 6 weeks QTL 3 11: 35100995-35120899 2.622682 
n-R5s44, nuclear encoded rRNA 5S 44 14: 9797430-9881986 2.509633 
Synpr, synaptoporin 14: 14202231-14220929 2.488148 
Cadps, Ca2+-dependent secretion activator 14: 13452033-13505602 2.469775 
Dym, dymeclin 18: 75261748-75269685 2.411058 
Idd21.1, insulin dependent diabetes susceptibility 21.1 18: 75261748-75269685 2.411058 
Pgis1, proteoglycan induced spondylitis 1 18: 75261748-75269685 2.411058 
Atxn7, ataxin 7 14: 14797756-14919236 2.400826 
Prdt2, prion disease incubation time 2 2: 178866494-178868269 2.399079 
Rpl21-ps4, ribosomal protein L21, pseudogene 4 14: 12042049-12079505 2.389314 
Scgq3, spontaneous crescentic glomerulonephritis QTL 3 2: 164473694-164543019 2.387713 
Spint4, serine protease inhibitor, Kunitz type 4 2: 164473694-164543019 2.387713 
Wfdc10, WAP four-disulfide core domain 10 2: 164473694-164543019 2.387713 
Wfdc11, WAP four-disulfide core domain 11 2: 164473694-164543019 2.387713 
Wfdc13, WAP four-disulfide core domain 13 2: 164473694-164543019 2.387713 
Wfdc9, WAP four-disulfide core domain 9 2: 164473694-164543019 2.387713 
Rthyd3, resistance to thymic deletion 3 14: 13387864-13423496 2.386053 
Tmc1m4, Tmc1 modifier 4 5: 104462697-104463002 2.382099 
Fezf2, Fez family zinc finger 2 14: 13308624-12210361 2.32838 
Thoc7, THO complex 7 homolog (Drosophila) 14: 14772525-14930217 2.314043 
Bmd4, bone mineral density 4 15: 56618365-56626586 2.297213 
Lrrc3b, leucine rich repeat containing 3B 14: 16208056-16246773 2.285353 
Ity2a, immunity to S. typhimurium 2a 11: 52134589-52150216 2.281033 
Ath13, atherosclerosis 13 14: 82146864-82154961 2.278372 
Plast1, plasma plant sterol 1 14: 82146864-82154961 2.278372 
Plast1b, plasma plant sterol 1b 14: 82146864-82154961 2.278372 
Mob5, multigenic obesity 5 2: 110016970-110066102 2.257479 
Plast2b, plasma plant sterol 2b 2: 110016970-110066102 2.257479 
T2dm2sa, type 2 diabetes mellitus 2 in SMXA RI mice 2: 110016970-110066102 2.257479 
Bglu1, blood glucose level 1 2: 164422011-164543944 2.250826 
Wfdc16, WAP four-disulfide core domain 16 2: 164422011-164543944 2.250826 
Wfdc6b, WAP four-disulfide core domain 6B 2: 164422011-164543944 2.250826 
Wfdc8, WAP four-disulfide core domain 8 2: 164422011-164543944 2.250826 
Olfr720, olfactory receptor 720 14: 14996243-15046024 2.24221 
Alan2, alloantigen response 2 4: 141503560-141529979 2.234897 
Athsq1, atherosclerosis susceptibility QTL 1 4: 141503560-141529979 2.234897 
Bmd7, bone mineral density 7 4: 141503560-141529979 2.234897 
Cinda3, cytokine induced activation 3 4: 141503560-141529979 2.234897 
Fhad1, forkhead-associated (FHA) phosphopeptide binding domain 
1 
4: 141503560-141529979 
2.234897 
Lama1, laminin, alpha 1 17: 68051652-68076393 2.22981 
Pregq4, pregnancy QTL 4 17: 68051652-68076393 2.22981 
Psmd6, proteasome 26S subunit, non-ATPase, 6 14: 14725549-15046584 2.222066 
Tbqt5, tibia bone quality traits 5 13: 107080581-107145390 2.205249 
Appd2, APP associated premature death 2 14: 17565088-17626508 2.174883 
Tmc1m1, Tmc1 modifier 1 2: 110016289-110086903 2.166578 
Nek10, NIMA (never in mitosis gene a)- related kinase 10 14: 15683725-15694698 2.165838 
Olfr31, olfactory receptor 31 14: 15106114-15169235 2.14145 
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Abstract 
Background 
 Omega 3 (n-3) fatty acids (FAs) have been found to inhibit proliferation, induce 
apoptosis, and promote differentiation in various cell types. The processes of cell 
survival, expansion, and differentiation are of key importance in the regulation of 
hematopoiesis. We investigated the role of n-3 FAs in controlling the frequency of 
various myeloid progenitor cells in the bone marrow of mice. Increased progenitor cell 
frequency and blocked differentiation are characteristics of hematopoietic disorders of the 
myeloid lineage, such as myeloproliferative diseases and myeloid leukemias. 
Results 
 We found that increasing the proportion of n-3 FAs relative to the proportion of 
omega 6 (n-6) FAs in the diet caused increased differentiation and reduced the frequency 
of myeloid progenitor cells in the bone marrow of mice. Furthermore, increasing the 
proportion of n-3 FAs relative to the proportion of omega 6 (n-6) FAs in the diet had no 
adverse effect on peripheral white blood cell counts. 
Conclusion 
 Our results indicate that n-3 FAs impact hematopoietic differentiation by reducing 
myeloid progenitor cell frequency in the bone marrow and promoting progenitor cell 
differentiation. Further exploration of this discovery could lead to the use of n-3 FAs as a 
therapeutic option for patients that have various disorders of hematopoiesis.   
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Introduction  
 n-3 and n-6 FAs are essential FAs that must be obtained from dietary sources. 
Recently, the ratio of n-3 to n-6 FAs consumed in the diet has been studied in relevance 
to cardiac health [1], neurological health [2], and cancer prevention [1]. n-3 FAs can 
compete with n-6 FAs for the same metabolic enzymes. n-3 and n-6 FAs are incorporated 
into cell membranes either directly or after elongation and desaturation by Δ4, Δ5, and 
Δ6 desaturases [3, 4]. n-3 FAs have greater affinity for the Δ4 and Δ6 desaturases than n-
6 FAs [5-7]. Dietary linoleic acid (18:2, n-6) is generally considered to be the major 
source of tissue arachidonic acid (20:4, n-6) although meat fat can be a direct source of 
arachidonic acid [8]. All three major n-3 FAs, α linolenic acid (18:3), eicosapentanoic 
acid (20:5), and docosahexanoic acid (22:6), directly inhibit the production of 
arachidonic acid from linoleic acid [5]. Both arachidonic acid and eicosapentanoic acid 
can be cleaved from the cell membrane phospholipid stores by phospholipase A2 and 
acted on by cyclooxygenases (either the constitutive COX1 or the inducible COX2) to 
produce prostaglandin precursors that are isomerized by prostaglandin synthases to 
produce prostaglandins. In this manner, COXs convert arachidonic acid to form the 2-
series prostaglandins that tend to be pro-proliferative and pro-inflammatory in most 
tissues [9]. Micromolar concentrations of prostaglandin E2 (PGE2) increase human 
myeloid progenitor cell proliferation [10]. However, COX activity on eicosapentanoic 
acid forms the 3 series prostaglandins that tend to have anti-proliferative and anti-
inflammatory properties [9]. In addition to prostaglandins, leukotrienes and eicosanoids 
are formed from FAs through the activity of various lipoxygenases. These have been 
shown to have varying and sometimes controversial effects on either hematopoietic stem 
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cell or myeloid progenitor cell differentiation [10, 11]. Thus, a model system approach is 
needed to effectively dissect the net effect of dietary FAs on hematopoiesis in vivo. 
Abnormal hematopoiesis often involves expansion of immature cells of the myeloid 
lineage. In these cases, progenitor cell frequency could be expanded by increased 
proliferation, decreased apoptosis, or both. If n-3 FAs inhibit proliferation or induce 
apoptosis in myeloid progenitor cells, they could alleviate the cellular expansion that 
occurs in certain disorders of hematopoiesis. Another characteristic of these disorders is a 
block in differentiation. During normal hematopoiesis, a continuum of differentiation 
exists, such that long term hematopoietic stem cells progressively differentiate to produce 
terminally differentiated cells of the blood. Because n-3 FAs have been shown to promote 
differentiation [10], they may serve as a therapeutic tool [12-15] for disorders involving 
the inhibition of normal differentiation.  
 Our results indicate that the frequency of myeloid progenitors in the bone marrow 
of mice fed fish oil diets is two-fold less than in those fed corn oil diets. Our data also 
indicate that this reduction of progenitor cells does not have an adverse effect on the 
number of circulating white blood cells in the periphery, even after prolonged dietary 
change. These results suggest a possible role for n-3 FAs as therapeutic agents in 
disorders involving expansion of myeloid progenitors, such as the myeloid leukemias. 
Materials and methods  
Animals  
 Mice used in this study were FVB X sv129F1 hybrid mice. FVB mice were of a 
colony maintained by W. Elaine Hardman’s laboratory at Marshall University. They were 
initially attained from Jeffrey E. Green’s laboratory (Lab of Cell Regulation and 
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Carcinogenesis, National Cancer Institute, National Institute of Health, Bethesda, MD).  
Sv129 mice were purchased from Charles River Laboratories (Wilmington, MA). Only 
male mice were used to avoid cyclic changes in hormones. Mice were housed in the 
AAALAC accredited animal facilities of the Marshall University School of Medicine. All 
animal use and care was approved by the Marshall University Institutional Animal Care 
and Use Committee. The mice were housed 3 to 4 in a cage and individually numbered 
for identification.  
Diet  
 The base diet was an American Institute of Nutrition (AIN)-76A diet modified by 
substitution of 5% sucrose for 5% more oils to contain a total of 10% w/w oil (Tables 3.1 
and 3.2). The fish oil diet contained 3.65% n-3 FAs and 1.3% n-6 FAs. The corn oil diet 
contained 0.1% n-3 FAs and 6.1% n-6 FAs. Diets were prepared in the Marshall 
University School of Medicine animal diet prep room. Diet composition is shown in 
Table 3.1 and was formulated to be isocaloric, isonutrient and relevant to human 
consumption. The AIN-76A diet is adequate for the nutritional support of the mice [28]. 
The dry ingredients of the diet were obtained in bulk from MP Biomedicals (Solon, 
Ohio), sugar, corn and canola oil were purchased locally (100% canola oil, 100% corn 
oil, no additives or preservatives). The n-3 supplement (OmegaRx Liquid) was purchased 
from Zone Labs, Danvers, MA. Batches of diet were prepared as needed, about every two 
weeks. The diet mixture was pressed into trays and cut into small squares. Individual 
cage sized portions (25–30 g) were stored in sealed containers at -20°C to prevent 
oxidation of the fat and bacterial growth in the food. Mice had free access to food and 
water and were fed fresh food 5 days per week. Food removed from cages was discarded. 
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Colony forming cell (CFC) assays 
 FVB X sv129 F1hybrid mice were fed either a fish oil diet (n = 5) or a corn oil 
diet (n = 5) from weaning until 60 days old. CFC assays were then performed upon bone 
marrow isolated from these mice as previously discussed [29, 30]. Briefly, bone marrow 
was harvested by flushing from the femurs with Iscove's Modified Dulbecco's Medium 
(IMDM) and cells were counted and seeded in 4 well plates at a density determined 
empirically by a pilot study conducted with a broad and consistent range of seeding 
densities. After linear response of colony production to seeding density was ensured by 
the pilot study, seeding densities of 2.09 × 104 (fish oil) and 7.75 × 103 (corn oil) 
cells/well were chosen to produce 10–30 colonies for each well. Bone marrow was 
cultured in 1% semi-solid Methocult M3434 (StemCell Technologies), supplemented 
with 0.4% autochthonous sera. Cells were incubated for 6–7 days to allow colony 
formation. Colonies with a minimum cell number of 20 were scored as positive using an 
inverted microscope at 40X magnification. Colonies were counted based on 
morphological features that are associated with each progenitor type. Student's t type tests 
were used to detect differences between the experimental groups (n = 5). 
 
White blood cell counts 
 White blood cell counts were performed on EDTA anticoagulated peripheral 
blood from tail veins of corn and fish oil fed female mice aged 115 days. Fish and corn 
oil diets were instituted after weaning. Student's t type tests were used to detect 
differences between the experimental groups. 
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Results   
High levels of n-3 FAs alter the character of the myeloid progenitor cell 
compartment in the bone marrow  
 Progenitors for myeloid cells in bone marrow that can be assessed by CFC assays 
include granulocyte erythrocyte macrophage megakaryocyte (GEMM) progenitors, 
granulocyte macrophage (GM) progenitors, erythrocyte (E) progenitors, granulocyte (G) 
progenitors, and macrophage (M) progenitors. Only these progenitors have the necessary 
growth factors and proliferation capacity to produce colonies in the CFC assay. 
Morphology of these colony types is shown in Figure 3.1. Mice were fed fish oil (high 
level n-3 FAs) or corn oil (low level n-3 FAs) containing diets (Tables 3.1 and 3.2). Mice 
that were fed the fish oil diet had a significantly lower (p = 0.010) frequency of total 
myeloid progenitor cells (9.78 ± 0.46 × 10-4) than those mice fed the corn oil diet (2.10 ± 
0.55 × 10-3) (Fig. 3.2A). These results indicate that n-3 FAs were inducing a reduction in 
total myeloid progenitors in bone marrow. GM, G, and M progenitors were significantly 
less (p < 0.05) frequent in the bone marrow of mice fed the fish oil diet than those fed the 
corn oil diet (Fig. 3.2A). Interestingly, E progenitors did not change in their frequency 
with diet, indicating n-3 FAs preferentially affected levels of GM progenitors and their 
daughter cells (see Fig. 3.1). There was also an apparently larger frequency of GEMM 
progenitors, which are early progenitors, in corn oil (5.16 ± 4.32 × 10-5) vs. fish oil (1.20 
± 1.20 × 10-5) fed mice. Although this was a greater than 4 fold difference in frequency, 
the difference was not statistically significant (p = 0.11) and the rarity of this progenitor 
relative to others made it difficult to accurately assay with this technique. 
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 Analysis of the proportions of progenitor cells that make up the myeloid 
progenitor cell compartment in these mice revealed that mice fed a fish oil diet had a 
much different proportion of early and late stage progenitors compared to those fed a 
corn oil diet (p = 0.00015). There was a greater percentage of later stage progenitor cells 
(G, M, E progenitors) in fish oil diet fed mice (94.9 ± 1.6%) when compared to mice fed 
a corn oil diet (71.3 ± 4.8%) (Fig. 3.2B). Conversely, there was a greater proportion of 
earlier stage progenitors (GEMM and GM progenitors) in corn oil fed mice (28.7 ± 4.8%) 
vs. fish oil fed mice (5.15 ± 1.6%). Thus, our data indicate that the bone marrow of mice 
fed a high level of n-3 FAs had a more differentiated myeloid progenitor cell 
compartment than that of mice fed a diet containing mostly n-6 FAs. 
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Figure 3.1. Hematopoiesis differentiation continuum – myeloid progenitor 
morphology. Hematopoiesis exists as a continuum of differentiation. Colony 
morphology representing the various myeloid progenitor cells is shown (magnification = 
100×) in a differentiation hierarchy beginning with the least differentiated progenitor and 
continuing to the most differentiated progenitor. Abbreviations: Granulocyte erythrocyte 
macrophage megakaryocyte (GEMM), granulocyte macrophage (GM), erythrocyte (E), 
granulocyte (G), macrophage (M). 
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Table 3.1:  Modified AIN-76A Diet Composition. 
 Diet composition
 
Ingredient % of weight Amount/100 g 
Casein (protein) 20% 20 g 
Sucrose 45% 45 g 
Corn starch (carbs) 15% 15 g 
Alphacel (fiber) 5% 5 g 
Choline bitartrate 0.2% 0.2 g 
DL-methionine 0.3% 0.3 g 
Mineral mix 3.5% 3.5 g 
Vitamin mix 1.0% 1 g 
   
Fat 10% 10 g 
Total 100% 100 g 
   
Total fat  10 g 
Total protein  20 g 
Total carbohydrate  60 g 
The base diet is an AIN-76A diet modified by substitution of 5% sucrose for 5% more oils to contain a 
total of 10% w/w oil. The mouse food recipe contains 10% fat in each diet supplied through these oils. 
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Table 3.2: Compositions of dietary fats (approximate %). 
 Saturated fatty acids 
Linoleic acid 
(omega 6) Total omega 3
Monounsaturated fatty 
acids 
Corn oila 13 61 1 26 
Canola 
oila 6 20 10 62 
n-3 suppb 9 6 63 21 
The corn oil diet is the low omega 3:omega 6 fatty acid diet containing 10% w/w corn oil as the source 
of all fat. The fish oil diet is our high omega 3:omega 6 fatty acids diet containing 5% w/w canola oil 
and 5% w/w omega 3 fatty acid supplement. The corn oil diet contains 0.1% omega 3 fatty acids and 
6.1% omega 6 fatty acids, which is a relative ratio of omega 6 to omega 3 of 61: 1. The fish oil diet 
contains 3.65% omega 3 fatty acids and 1.3% omega 6 fatty acids, which is a relative ratio of 1: 2.8. 
aFrom: http://www.nal.usda.gov/fnic/foodcomp/search 
bFrom: Manufacture's certified analyses. 
 
 
81 
 
 
 
Figure 3.2: Fish oil diets cause changes in the steady state levels of myeloid 
progenitors in the bone marrow. A. Colony forming cell (CFC) assay results of bone 
marrow from mice fed corn oil (high n-6) vs. fish oil (high n-3) diets until 60 days of age. 
Colonies formed represent the presence of a progenitor cell in which the type of colony 
determines which progenitor cell type is present. Comparisons marked with (*) were 
found to be significantly different (p < 0.05). Error bars represent SEMs (n = 5). B-C. 
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Data from A in which each colony type is shown as a proportion of total progenitor cell 
frequency for each diet. 
 
High levels of n-3 FAs do not have an adverse effect on white blood cell production 
in the peripheral blood 
 To account for the concern that a lower progenitor cell frequency or a greater 
proportion of differentiated progenitor cells in the bone marrow may cause a reduction in 
white blood cells in peripheral blood and therefore a weakened immune system, we 
performed white blood cell (WBC) counts on mice fed these diets from weaning to 115 
days. Results indicated no significant differences in peripheral WBC counts between corn 
oil fed mice (14,825 WBC/μl) and fish oil fed mice (13,760 WBC/μl) (Fig. 3.3). Thus, 
fish oil diets induce a homeostatic condition of decreased progenitor cell frequency in the 
myeloid compartment of the bone marrow without adverse effects on WBC production. 
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Figure 3.3: Fish oil diets do not cause adverse reduction of white blood cell counts in 
the peripheral blood. White blood cell (WBC) counts in WBC/μl from female mice on 
the two diets until 115 days of age (n = 4 for fish oil, n = 5 for corn oil, p = 0.602). Error 
bars represent SEMs. 
 
Discussion  
 Our results indicate that n-3 FAs reduce total myeloid progenitor cell frequency 
and promote differentiation of specific progenitor cell types in the bone marrow of mice. 
Furthermore, this reduction of progenitors does not have an adverse effect on levels of 
circulating white blood cells. Our data indicate that n-3 FA effects are particular to 
granulocyte and macrophage progenitor cells rather than erythrocyte maturation. The 
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effects of n-3 FAs may occur as early in maturation as the GEMM progenitor stage and 
then be propagated to the GM and later progenitor stages. While our results indicate a 
difference at the GM progenitor stage, they are also suggestive, although inconclusive, of 
a difference at the GEMM stage. We are currently examining this question with ongoing 
experiments to look at the earliest stem and progenitor cell stages of hematopoiesis.  
 Examination of the effects of n-3 FAs on hematopoiesis could lead to potential 
therapeutic options for patients with disorders of the blood. Future work would include 
investigating the mechanisms of action for these events. Mechanisms by which n-3 FAs 
have been shown to inhibit proliferation, induce apoptosis, and promote differentiation in 
many cancers include the regulation of signaling pathways and gene expression by 
peroxisome proliferator receptor activator γ (PPARγ), for which n-3 FAs are natural 
ligands [16]. Another mechanism of action of n-3 FAs includes inhibition of COX2, 
which is upregulated in various cancers and is known to have proproliferative and 
antiapoptotic effects [17-25]. Furthermore, the combination of activating PPARγ and 
inhibition of COX2 expression has recently been shown to inhibit proliferation and 
induce apoptosis in pancreatic cancer [26]. We plan to explore these, among other 
mechanisms, using our animal model. 
 Regardless of the mechanisms by which n-3 FAs reduce and differentiate myeloid 
progenitor cells in the bone marrow of mice, these dietary agents serve as a promising 
option for therapy. The inhibitory effect of n-3 FAs on immune system function [10, 27] 
has led to the use of fish oils that are high in these FAs in the management of several 
inflammatory and autoimmune diseases [27]. Suppression of n-6 derived eicosanoids has 
been proposed as a strategy for chemoprevention and as an adjunct for treatment of 
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cancer [12-15]. Our results suggest that using n-3 FAs to more rapidly differentiate 
myeloid progenitor cells may slow progression of disorders of hematopoiesis, including 
leukemias, and restore a more normal myeloid progenitor cell compartment in the bone 
marrow. 
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Abstract 
 The effects of the polyunsaturated omega-3 (n-3) and omega-6 (n-6) fatty acids 
(FAs) on hematopoiesis are complex in that both FA forms are processed into 
leukotrienes, eicosanoids, and prostaglandins, which can have independent effects. These 
FAs have antagonistic effects in that n-6 FA prostaglandins tend to be pro-proliferative 
and pro-inflammatory, whereas the effects of n-3 FA prostaglandins are the opposite. We 
have previously shown that diets high in n-3 FAs reduce the size of the middle to later 
stage myeloid progenitor compartment in FVB X sv129 F1hybrid mice. To assay the 
effects of high n-3 FA diets on earlier stages of myelopoiesis, we fed C57BL/6J mice 
diets high in n-3 FAs or at levels of n-3:n-6 FAs similar to western diets and assayed the 
effects on myelopoiesis with flow cytometry and colony forming cell (CFC) assays. 
Results indicate an expansion of the common myeloid progenitor cell compartment in 
high n-3 FA diets, which does not persist into later stages where the number of progenitor 
cells is actually lower in high n-3 FA fed animals. Investigations in vitro with the 
hematopoietic stem cell line EML-clone 1 indicate that cells cultured with 
eicosapentanoic acid (n-3 FA) or arachidonic acid (n-6 FA) have no differences in cell 
viability but that arachidonic acid more rapidly produces progenitors with low levels of 
the macrophage developmental marker, F4/80. 
 
Key words: Omega fatty acids, EPA, DHA, immunology, stem cells, progenitor cells, 
bone marrow, nutrition 
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Introduction 
 The examination of omega-3 (n-3) and omega-6 (n-6) fatty acids (FAs) effects on 
hematopoiesis is important to patient care. The inhibitory effect of n-3 FAs on 
inflammation has led to the use of fish oils that are high in these FAs in the management 
of several inflammatory and autoimmune diseases [1]. n-3 FAs affect hematopoietic 
differentiation by influencing myeloid progenitor cells [2]. n-3 FAs are known to affect 
immune system function by reducing several aspects of neutrophil, monocyte, and 
lymphocyte function [1]. Suppression of n-6 derived eicosanoids has been proposed as a 
strategy for chemoprevention and as an adjunct for treatment of cancer [3-6]. 
 n-3 and n-6 FAs are incorporated into cell membranes either directly or after 
elongation and then desaturation by 6 and 5 desaturases. Dietary linoleic acid (LNA, 
18 carbons, n-6 FA) is generally considered to be the major source of tissue arachidonic 
acid (ARA, 20 carbons, n-6 FA) although meat fat can be a direct source of ARA [7]. n-3 
FAs have greater affinity for the 5 and 6 desaturases than n-6 FAs. Consequently, 
increasing dietary intake of n-3 FAs reduces the desaturation of LNA and reduces the 
production of ARA [8]. All three major n-3 FAs – α linolenic acid (ALA, 18:3, n-3), 
eicosapentanoic acid (EPA, 20:5, n-3), and docosahexanoic acid (DHA, 22:6, n-3) – 
directly inhibit the production of ARA from LNA [8]. 
 Both ARA and EPA can be cleaved from the cell membrane phospholipids stores 
by phospholipase A2 and acted on by cyclooxygenases (either the constitutive COX1 or 
the inducible COX2) to produce prostaglandin precursors which are isomerized by 
prostaglandin synthases to produce prostaglandins. COX activity on ARA forms the 2-
series prostaglandins that tend to be pro-proliferative and pro-inflammatory in most 
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tissues [9]. Micromolar concentrations of prostaglandin E2 increase human myeloid 
progenitor cell proliferation [2]. However, COX activity on EPA forms the 3 series 
prostaglandins that tend to have anti-proliferative and anti-inflammatory properties [9]. In 
addition to prostaglandins, leukotrienes and eicosanoids are formed from FAs through 
activity of various lipoxygenases. These have been shown to have varying and sometimes 
controversial effects on either hematopoietic stem cell or myeloid progenitor cell 
differentiation [2, 10]. A model system approach is needed to effectively dissect the net 
effect of dietary FAs on hematopoiesis in vivo. 
 In this study, we examined the effects of n-3 and n-6 FAs in vivo in the mouse, 
with an analysis at the level of stem and progenitor subtypes. Our results indicate that, 
compared to diets rich in n-6 FAs, diets rich in n-3 FAs induce lower levels of later stage 
myeloid progenitor cells in mice but that there is a higher frequency of the earliest stage 
myeloid progenitor cells in these mice. Our in vitro results indicate that aspects of the in 
vivo effects of n-3 and n-6 FAs can be modeled using the EML cell culture system to 
ascertain the mechanisms involved. 
 
Materials and methods 
Animals 
 C57BL/6J mice used in this study were purchased from The Jackson Laboratory 
(Bar Harbor, ME). Only male mice were used to avoid cyclic changes in hormones. Mice 
were housed in the AAALAC accredited animal facilities of the Marshall University 
School of Medicine. All animal use and care was approved by the Marshall University 
Institutional Animal Care and Use Committee. The mice were housed 3 to 4 in a cage and 
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individually numbered for identification. Mice were fed either a fish oil diet (n=8) or a 
corn oil diet (n=8) from 6 weeks of age until 20 wks of age (100 days on diet). 
 
Diet 
 The base diet was an American Institute of Nutrition (AIN)-76A diet modified by 
substitution of 5% sucrose for 5% more oils to contain a total of 10% w/w oil (Tables 4.1 
and 4.2). The fish oil diet contained 3.65% n-3 FAs and 1.3% n-6 FAs. The corn oil diet 
contained 0.1% n-3 FAs and 6.1% n-6 FAs. Diets were prepared in the Marshall 
University School of Medicine animal diet prep room. Diet composition is shown in 
Table 4.1 and was formulated to be isocaloric, isonutrient and relevant to human 
consumption. The AIN-76A diet is adequate for the nutritional support of the mice [11]. 
The dry ingredients of the diet were obtained in bulk from MP Biomedicals (Solon, 
Ohio): sugar, corn and canola oil were purchased locally (100% canola oil, 100% corn 
oil, no additives or preservatives). The n-3 supplement (OmegaRx Liquid) was purchased 
from Zone Labs, Danvers, MA. Batches of diet were prepared as needed, about every two 
weeks. The diet mixture was pressed into trays. Food (25-30 g) was stored in sealed 
containers at -20°C to prevent oxidation of the fat and bacterial growth in the food. Mice 
had free access to food and water and were fed fresh food 5 days per week. Food 
removed from cages was discarded. 
 
Colony forming cell (CFC) assays 
 CFC assays were performed upon bone marrow isolated from C57BL/6 mice as 
previously discussed [12, 13]. Briefly, bone marrow was harvested by flushing from the 
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femurs with Iscove’s modified Dulbecco’s medium and cells were counted and seeded in 
4 well plates in at a density determined empirically by a pilot study conducted with a 
broad and consistent range of seeding densities. After linear response of colony 
production to seeding density was ensured by the pilot study, seeding densities were 
chosen to produce 10-30 colonies for each well (4-well plates). Bone marrow was 
cultured in 1% semi-solid Methocult M3434 (StemCell Technologies) supplemented with 
0.4% autochthonous sera. Cells were incubated for 6-7 days to allow colony formation. 
Colonies with a minimum cell number of 20 were scored as positive using an inverted 
microscope at 40X magnification. Colonies were counted based on morphological 
features that are associated with each progenitor type. 
 
Flow cytometry 
 The preparation of bone marrow for flow cytometry was performed as previously 
described [12]. Erythroid myeloid lymphoid (EML) cells were prepared by washing twice 
with FACS buffer (PBS supplemented with 0.5% bovine serum albumin and 2mM 
EDTA) and collecting by centrifugation. Thereafter, samples were incubated with 2% 
autochthonous sera obtained from cardiac puncture just before marrow harvest to prevent 
nonspecific binding by blocking the Fc receptors for 30 minutes at 4°C. The cells were 
washed again and labeled with antibodies for 30 minutes on ice. The following antibodies 
were used in the bone marrow studies with Streptavidin-Pacific Blue to detect 
biotinylated antibodies: PE-Cy7 conjugated Sca-1 (clone D7, eBiosciences #25-5981-81), 
APC-eFluor 750 conjugated CD117 (clone 2B8, eBiosciences #47-1171-80), biotinylated 
lineage panel (BD Biosciences #559971), biotinylated IL-7Rα (clone B12-1, BD 
95 
Biosciences #555288), APC conjugated FCRγ (clone 93, eBiosciences #17-0161-81), and 
PE conjugated CD34 (clone RAM34, BD Biosciences 551387). The following antibodies 
were used in labeling the EML-clone1 cells in labeling pairs with Streptavidin-APC (BD 
Biosciences #554067) to detect biotinylated antibodies: biotinylated Ly6G/C (clone RB6-
8CS, BD Biosciences #553125) + PE conjugated CD117 (clone 2B8, BD Biosciences 
#553355), biotinylated CD11b (clone M1/70, BD Biosciences #553309) + PE conjugated 
Sca-1 (clone D7, BD Biosciences #553108), and biotinylated CD45 (clone RA3-6B2, BD 
Biosciences #553086) + PE conjugated F4/80 (clone BM8, Caltag #MF48004). Data 
acquisition was performed using BD FACS Aria I sorter and data analysis and 
compensation was performed using FlowJo v. 7.6 software (Treestar, Ashland, OR) with 
super-enhanced Dmax subtraction analysis for determination of small differences in 
overlapping histograms. Algorithms for super-enhanced Dmax analysis are used to 
calculate the percentage of positive cells found in the sample and not the control by 
allowing for a quantitative subtraction of non-specific fluorescence. 
 
In vitro culture and differentiation 
 EML C1 cells were the kind gift of Dr. Schickwann Tsai (University of Utah, Salt 
Lake City, UT) and were maintained in Iscove’s modified Dulbecco medium (IMDM,) 
supplemented with 20% horse serum (American Type culture collection, ATCC, 
Manassas, VA) and 10% baby hamster kidney (BHK)/MKL cell conditioned medium 
[14]. For differentiation studies, EML cells were induced to differentiate into myeloid 
cells with 10μM all-trans retinoic acid (ATRA; Sigma, St. Louis, MO, USA), 10% BHK 
cell conditioned medium (source of stem cell factor) and 15% WEHI (monocyte cell line) 
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cell conditioned medium (source of interleukin-3) for three days. EML-clone1 cells 
were seeded at 2x105 cells/mL and cultured for 24 hours in 60μM FAs in standard growth 
medium (20% horse serum, 70% Dulbecco’s modified eagle medium, and 10% BHK cell 
conditioned medium). After 24 hours cells were placed in differentiation medium with 
60μM FAs at 2.0x105 cells/mL. Cell counts were performed using trypan blue at 24, 48, 
72, and 96 hours. After 96 hours cells were processed for flow cytometry analysis. 
 
Fatty acid metabolism studies 
 Cells were seeded at 2x105 cells/mL and treated with vehicle control of ethanol or 
60μM FAs. The ethanol vehicle control was added in the same concentrations as FAs. 
Cell counts were performed at 24, 48, 72, and 96 hours using trypan blue. At each time 
point, half the total volume of the culture was taken as a sample and replaced with 
untreated growth media. Each sample was centrifuged (500xg), the supernatant removed, 
and the pellet stored at -20°C until analyzed by gas chromatography. At the time of gas 
chromatography, cells were homogenized in 0.1% butylated hydroxytoluene in 70% 
methanol/distilled water to prevent FA oxidation. Lipids were extracted with 
chloroform/methanol and methylated. Methylated lipids were separated and identified 
using gas chromatography as previously published [15]. FA methyl ester standards (Nu-
Chek-Prep, Elysian, MN) were used for peak identification. The FA methyl esters were 
reported as the percent of the total methylated FAs (area under the curve).  
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Statistical analysis 
 Statistical analyses were run using SAS software release 9.2 (SAS Institute Inc. 
Cary, NC). Student’s t-tests were used to detect differences between the experimental 
groups (corn oil versus fish oil diet) of colony forming cells (n=8 for each group) and 
between the experimental groups (corn oil versus fish oil diet) in flow cytometry assays 
(n = 8 for each group). To determine statistical significance in gas chromatography 
experiments and differentiation studies the levels of FAs of a particular type were 
analyzed using either one-way analysis of variance (ANOVA) or by one-way Kruskal-
Wallis analysis of variance on ranks. Dunnett multiple comparison tests were used for 
testing if any treatments are significantly different from a single control for all main 
effects means in the MEANS statement. 
 
Results 
Fish oil diets induce changes in the frequency of various myeloid progenitor cell 
types in the bone marrow 
 In our previous investigations of the effect of fish oil diets on murine 
hematopoiesis, we found a down-regulation in the frequency of myeloid progenitor cells 
in bone marrow in mice fed fish oil diets compared to those on corn oil diets[16]. Other 
investigators have reported that bone marrow of rodents readily changes composition 
based upon dietary FA sources [17]. However, our investigations using CFC assays 
limited our ability to assay the frequency of more immature cell types, such as the 
common myeloid progenitor (CMP, same as GEMM) and hematopoietic stem cell 
(HSC). In order to assay the effects of high n-3 FA diets on these cell types, we verified 
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that the effects seen in FVB X sv129 F1 hybrid animals were also seen in C57BL/6 mice 
in which flow cytometry markers for examining these rare cell types have been verified 
[18]. In the experiments presented here, mice were fed diets rich in n-3 FAs (fish oil diet) 
or rich in n-6 FAs (corn oil diet) from 6 weeks of age until 20 wks of age (Tables 4.1 and 
4.2, 100 days on diet). Bone marrow was then harvested and analyzed by colony forming 
cell assay and flow cytometry. There was no difference in density of cells in the bone 
marrow (Fig. 4.1A). Our results (Fig. 4.1B) indicated an overall lower frequency of mid 
to late stage progenitors when mice were fed n-3 FA rich diets compared to those that 
were fed n-6 FA rich diets. There was a significantly lower (26%, p-value < 0.01) overall 
myeloid progenitor cell frequency, with significant reductions (p-value < 0.05) in colony 
forming unit granulocyte-macrophage (CFU-GM) and colony forming unit macrophage 
(CFU-M). 
 When we examined the relative contributions of each progenitor cell type to the 
overall myeloid progenitor cell pool in the bone marrow (Fig. 4.1C), we found that there 
is a significant reduction in CFU-GM proportion in mice on the fish oil diet (p-value < 
0.05). The comparison of proportions of subtypes of myeloid progenitors is different 
from what we observed in FVB X sv129 F1 hybrid mice [16], where we observed an 
overall shift to more later stage progenitor types [16]. Thus, though there was a reduction 
in myeloid progenitor cell frequencies in the marrow and a two-fold reduction in 
proportion of CFU-GM, there was little shift in proportions of the other progenitor 
subtypes. This difference may be due to particular characteristics of the C57BL/6 inbred 
strain that are not seen in F1 hybrid animals, possibly including the lessening of 
homozygous recessive mutations in hybrid animals. In a previous publication, we have 
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shown that mice vary significantly in myeloid progenitor cell frequencies [12]. These 
data indicate that C57BL/6 mice responded to high n-3 FA diets with a reduction in 
overall myeloid progenitor cell frequencies and significantly altering the proportions of 
the CFU-GM present. 
 
Table 4.1: Modified AIN-76A Diet Composition. 
 Diet composition
Ingredient % of weight Amount/100 g 
Casein (protein) 20% 20 g 
Sucrose 45% 45 g 
Corn starch (carbs) 15% 15 g 
Alphacel (fiber) 5% 5 g 
Choline bitartrate 0.2% 0.2 g 
DL-methionine 0.3% 0.3 g 
Mineral mix 3.5% 3.5 g 
Vitamin mix 1.0% 1 g 
   
Fat 10% 10 g 
Total 100% 100 g 
   
Total fat  10 g 
Total protein  20 g 
Total carbohydrate  60 g 
The base diet is an AIN-76A diet modified by substitution of 5% sucrose for 5% more oils to 
contain a total of 10% w/w oil. The mouse food recipe contains 10% fat in each diet supplied 
through these oils. 
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Table 4.2: Compositions of dietary fats (approximate %). 
 Saturated fatty acids 
Linoleic acid 
(omega 6) Total omega 3
Monounsaturated fatty 
acids 
Corn oila 13 61 1 26 
Canola 
oila 6 20 10 62 
n-3 supp.b 9 6 63 21 
The corn oil diet is the low omega 3:omega 6 fatty acid diet containing 10% w/w corn oil as the 
source of all fat. The fish oil diet is our high omega 3:omega 6 fatty acids diet containing 5% w/w 
canola oil and 5% w/w omega 3 fatty acid supplement. The corn oil diet contains 0.1% omega 3 fatty 
acids and 6.1% omega 6 fatty acids, which is a relative ratio of omega 6 to omega 3 of 61: 1. The fish 
oil diet contains 3.65% omega 3 fatty acids and 1.3% omega 6 fatty acids, which is a relative ratio of 
1: 2.8. 
aFrom: http://www.nal.usda.gov/fnic/foodcomp/search 
bFrom: Manufacture's certified analyses. 
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Figure 4.1: Reduction in middle to latter stage myeloid progenitor cell types by high 
n-3 diet. Mice were fed either corn oil or fish oil diets for 100 days followed by 
harvesting of bone marrow from femurs. A. The number of cells harvested from the mice 
on the different diets was similar. B. Colony forming cell assays were performed to 
enumerate the frequency of middle to latter stage progenitor types. The frequency of each 
progenitor cell type is shown. C. The relative distribution of progenitor types in the total 
progenitors assayed is shown. Significant differences as measured by Student’s t-tests (p-
value < 0.05) are indicated by *. Error bars represent SEM (n=8). SEMs in (C) for the 
corn oil diet data are BFU-E: 2.4%, CFU-GEMM: 0.8%, CFU-GM: 1.1%, CFU-G: 2.7%, 
CFU-M: 1.8% and for the fish oil diet are BFU-E: 2.4%, CFU-GEMM: 0.6%, CFU-GM: 
0.5%, CFU-G: 2.1%, CFU-M: 2.1%. Abbreviations are: colony forming unit (CFU), blast 
forming unit (BFU), granulocyte erythrocyte monocyte macrophage (GEMM), 
erythrocyte (E), granulocyte monocyte (GM), granulocyte (G), and macrophage (M). 
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The frequency of the common myeloid progenitor fraction is increased in mice fed 
fish oil diets  
 In order to assay the frequencies of earlier stage stem and progenitors cells in 
mice fed corn and fish oil diets, flow cytometry studies were conducted using established 
gating parameters from the Weissman lab [18] for the assay of HSCs, CMPs, 
granulocyte-macrophage progenitors (GMPs), and megakaryocyte-erythrocyte 
progenitors (MEPs) in C57BL/6 mice (Fig. 4.2A). Bone marrow cells were first gated by 
excluding high and low forward scatter cells along with those labeled positively for one 
of the differentiation antigens (refer to Table 4.3) in the lineage panel or IL-7Rα, which 
marks lymphoid cells. This population of FSCmidIL-7Rα–Lin–  cells was further gated into 
stem (FSCmidIL-7Rα–Lin–Sca-1+c-Kit+) and progenitor (FSCmidIL-7Rα–Lin–Sca-1–c-Kit+) 
cell fractions by expression of c-Kit and Sca-1 as shown. The progenitor pool was also 
analyzed and gated based upon the expression of CD34 and FcγR to delineate CMPs 
(FSCmidIL-7Rα–Lin–Sca-1+c-Kit+FcγRloCD34+), GMPs (FSCmidIL-7Rα–Lin–Sca-1+c-
Kit+FcγRhiCD34+), and MEPs (FSCmidIL-7Rα–Lin–Sca-1+c-Kit+FcγRloCD34–). These 
data show a 50% increase (p-value = 0.01) in the frequency of the CMP fraction in mice 
fed fish oil diets (Fig. 4.2B). There were no significant differences in frequency of HSC, 
GMP, or MEP fractions indicated in these studies. These data suggest that the frequency 
of the CMP has been increased by administration of a diet containing high levels of n-3 
FAs. 
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Table 4.3: Flow cytometry markers for gating populations of stem and early 
myeloid progenitor cells. 
Flow Cytometry Marker Cell Population Positive for Marker 
Lineage panel Differentiated cells 
IL-7Ra Lymphocyte progenitors 
Sca-1 Stem cells 
C-kit Stem and progenitor cells 
FcR MEPs and CMPs - low positive 
GMPs - high positive  
CD34 GMPs and CMPs 
 
 
 
Figure 4.2: Increase in early myeloid progenitors by high n-3 diets. Mice were fed 
either corn oil or fish oil diets for 100 days followed by harvesting of bone marrow 
from femurs. A. Representative plots are displayed to show gating parameters. Bone 
marrow cells were analyzed by flow cytometry first by FSC X lineage panel + IL7Rα 
(left panel). R1 represents the population of undifferentiated cells of the myeloid lineage.  
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This population was further analyzed by C-kit and Sca-1 expression, allowing for the 
gating of the HSC and R2 populations. R2 represents early progenitor cell populations. 
The R2 population was further analyzed and gated into CMP, GMP, and MEP 
populations based on FcγR X CD34 expression. B. The percentage of the total marrow 
cells labeling positive for each fraction are shown. Significant differences as measured by 
Student’s t-tests (p-value <0.05) are indicated by *. Error bars represent SEM (n=8). 
Abbreviations are: hematopoietic stem cells (HSCs), common myeloid progenitors 
(CMPs), granulocyte macrophage progenitors (GMPs), and megakaryocyte erythrocyte 
progenitors (MEPs).  
 
FAs applied to EML cell culture medium are incorporated and processed 
 In order to study the observed effects of n-3 vs. n-6 FAs on early myeloid 
progenitor cells in more detail, we examined the effects of the polyunsaturated FAs EPA 
and ARA on EML cells in culture. We chose to compare these two FAs because EPA 
(20:5, n-3) is the FAs most molecularly similar to ARA (20 carbons, n-6 FA) available. 
DHA (22:6, n-3) has two more carbons in the chain. The EML cell line is a stem cell 
factor dependent multipotent cell line with erythroid (E), myeloid (M), and lymphoid (L) 
potential. It was established from DBA/2 mouse bone marrow infected with a retroviral 
vector (LRARα403SN) harboring a dominant negative retinoic acid receptor [14]. It is a 
suspension cell line consisting of mostly blast like cells with 20-30% hand mirror shaped 
cells. EML cells serve as an excellent model to study hematopoietic differentiation. It can 
be induced to differentiate toward granulocyte/monocyte progenitors by high 
concentration of all-trans retinoic acid (ATRA) in the presence of interleukin-3 (IL-3). 
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 To verify the incorporation and processing by EML cells of FAs placed in the 
culture medium, we spiked the culture medium with 60μM ARA (Fig. 4.3A) or 60μM 
EPA (Fig. 4.3B) and analyzed the levels of various FAs present in the cells over the 
course of four days. Cells were analyzed with gas chromatography daily to determine the 
uptake and processing of FAs. The major FAs in untreated EML cell membranes are 
steric acid, oleic acid, LNA, and ARA (time 0). There are only faint traces of n-3 FAs 
such as ALA, EPA, docosapentanoic acid (DPA), and DHA in EML cell membranes 
under normal culturing conditions (time 0). In both cultures, the percentage of the major 
constituent of cell membranes (steric acid) is reduced as this is replaced by either ARA or 
EPA (Figs. 4.3A and 4.3B, 24 hours). Thus, FAs supplied in culture medium were being 
incorporated into cellular membranes and this occurs within 24 hours. Supplementation 
of ARA in the medium caused an increase in the already substantial levels of ARA in 
cellular membranes (Fig. 4.3A). There was a significant (p-value < 0.05) two-fold 
increase in ARA at 24 hours that drops to a 66% increase at 48 hours and was maintained 
for the remainder of the 4 days. The addition of EPA to the culture medium caused a 
significant (p-value < 0.001) increase in the n-3 FA EPA and elevated levels (p-value 
significant before correction for multiple comparisons) of the EPA elongation metabolite 
DPA, with a corresponding significant (p-value < 0.001) decrease in ARA by 24 hours 
(Fig. 4.3B). Interestingly, there was no increase in DHA, which is the 4 desaturase 
metabolite of DPA, indicating EML cells do not have this enzymatic activity. Thus, 
addition of FAs to the cell medium resulted in incorporation of FAs into cellular 
membranes and processing by 24 hours. 
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Figure 4.3: EML cells take up and metabolize FAs. EML cells were placed in growth 
medium containing 60μM arachidonic (A) or eicosapentanoic (B) acid. The uptake and 
processing of these FAs was assayed over the course of four days. Samples were taken 
just before addition of the FAs (t = 0), 24 hours, 48 hours, 72 hours, and 96 hours for 
analysis by gas chromatography. The gas chromatography data for each FA is shown 
above for the five data points in temporal order. Data displayed are the results of three 
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independent experiments with the mean and SEM displayed. Abbreviations: linoleic acid 
(LNA), alpha-linolenic acid (ALA), arachidonic acid (ARA), eicosapentanoic acid 
(EPA), docosapentanoic acid (DPA), and docosahexanoic acid (DHA). (*) indicate 
statistically significant (p-value < 0.05) differences based on one-way ANOVA test or 
Kruskal-Wallis test with Dunnett multiple comparisons adjustment. (**) indicate 
statistically significant (p-value < 0.05) differences based on Student’s t-test or Mann-
Whitney rank sum test without multiple comparison adjustment. 
 
Incubation of EML cells with FAs has effects on immunophenotype and cell 
proliferation 
 To determine if the effects of n-3 vs. n-6 FAs seen in our in vivo experiment are 
due to viability or proliferation differences induced by the FAs, we analyzed the effect of 
n-3 and n-6 FAs on EML cells in culture (Fig 4.4A) for two days, as we have shown that 
the greatest levels of incorporation of FAs supplied through the culture medium occur at 
24 hours according to the gas chromatography. EML cells in their native state are a 
model for hematopoietic stem cells. We found that cultures treated with 60μM ARA had 
significantly reduced (p-value < 0.05) cell counts after one day compared to the vehicle 
control. EPA treated cultures had slightly lower cell counts at day one, but the difference 
was not statistically significant. Neither of the treated cultures had statistically significant 
differences from the control at day 2, indicating that the effects of treatment with ARA 
were transitory. These results are consistent with the in vivo results, in which we saw no 
difference in the stem cell compartment of fish oil (high n-3) vs. corn oil (high n-6) fed 
mice. 
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 To observe cell autonomous effects of n-3 vs. n-6 FAs on cell viability and 
proliferation during GMP myeloid progenitor cell differentiation, we primed EML cells 
for 24 hours with 60μM EPA or ARA and then induced differentiation into 
macrophage/granulocytic lineages with ATRA, stem cell factor (SCF), and IL-3. After 
24, 48, and 72 hours in the differentiation medium, cell counts were performed on these 
EML cell cultures. Viability was measured by trypan blue dye exclusion (Fig. 4.4B). The 
viability of the cell cultures was very similar with the various treatments at each stage 
with a fairly consistent viability as the cultures differentiated (measured by non-stained 
cells/total cells, data not presented). There were no differences in viability when a one-
way ANOVA tests were run. All cultures were proliferating robustly with a doubling 
time starting at 18 hours and shortening as differentiation proceeded (data not presented). 
The major finding of this study was a significant reduction compared to control (p-value 
< 0.05) in cell counts in the EPA treatment group at days 2 (11% reduction) and 3 (21% 
reduction) with a suggestive reduction at day 1 (Fig. 4.4B). No reduction in viability of 
the cultures at these time points suggests that the difference was due to cell proliferation. 
These results are consistent with our in vivo results that show a higher frequency of 
middle-later stage myeloid progenitors with high n-6 diets. 
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Figure 4.4: In vitro culture of EML cells shows differences in cell proliferation 
between n-3 vs. n-6 treated cultures. A. EML cells in standard culture were treated with 
either vehicle control, arachidonic acid (n-6), or eicosapentanoic acid (n-3) for 48 hours 
with cell counts performed at 24 and 48 hours. B. EML cells were cultured in either 
vehicle control, arachidonic acid (n-6), or eicosapentanoic acid (n-3) for 24 hours then 
induced to differentiate for another 72 hours down myeloid lineages. Data displayed are 
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the results of two (A) or three (B) independent experiments with the mean and SEM 
displayed of culture counts normalized to the vehicle control. (*) indicate statistically 
significant (p-value < 0.05) difference based on one-way ANOVA test with Dunnett 
multiple comparisons adjustment. 
 
 To observe cell autonomous effects of n-3 vs. n-6 FAs on myeloid progenitor cell 
differentiation we primed EML cells for 24 hours with 60μM EPA or ARA and then 
induced differentiation into macrophage/granulocytic lineages with ATRA, SCF, and IL-
3. After 72 hours in the differentiation medium, EML cells were immunophenotyped for 
the early markers (refer to Table 4.4) Sca-1 and CD117, as well as the differentiation 
markers Ly6G, CD11b, CD45, and F4/80 (Fig. 4.5B). There were no significant 
decreases in Sca-1 levels (the first sign of differentiation in this model) with treatment, 
though the decrease with ARA treatment is suggestive (p-value significant before 
correction for multiple comparisons, but not after the appropriate Dunnett multiple 
comparison correction) when comparing treatments to vehicle control. There was a 
significant (p-value < 0.05) difference in the percentage of cells labeling with the F4/80 
antigen in the ARA treatment group compared to the vehicle control. The sizeable 
increase in F4/80 positive cells coupled with the suggestive decrease for the Sca-1 
antigen in the treatments with ARA compared to vehicle (Fig. 4.5B) indicates the 
production of a granulocyte/macrophage progenitor population with ARA treatment. 
These two results are consistent in that there is a lower frequency of the marker for stem 
cells and an increase in frequency of the differentiation marker F4/80. This result is also 
consistent with the in vivo data that found an increase in production of macrophage 
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progenitor subtypes at a later stage in the differentiation continuum of hematopoiesis 
(Fig.4.1B). The expression of F4/80 appears to be at a low abundance on a per cell basis 
in both ARA and EPA treated samples but much more prevalent in ARA treated samples 
(Fig. 4.5C). Thus, our model suggests that the differences in the common myeloid 
progenitor compartment in our in vivo experiment are not due to changes in rate of 
differentiation in the bone marrow and that n-6 FA supplementation produces a shift to 
macrophage/granulocytic lineages as seen in vivo. 
 
Table 4.4: Flow cytometry markers for gating populations at various stages in the 
differentiation continuum 
Flow Cytometry Marker Cell Population Positive for Marker 
Sca-1 Stem cells 
C-kit (CD117) Stem and progenitor cells 
F4/80 Early macrophages 
Ly6G Granulocytes 
CD11b Macrophages  
CD45 B-cells 
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Figure 4.5: No significant differences in myeloid progenitor cell maturation rate 
between n-3 and n-6 FAs. EML cells were cultured in either vehicle control, arachidonic 
acid (n-6), or eicosapentanoic acid (n-3) for 24 hours then induced to differentiate for 
another 72 hours down myeloid lineages. A. Flow cytometry was performed analyzing 
the larger FSC population of cells. B. The percentage of cells displaying various markers 
of differentiation is shown for each culture type. C. Representative histograms are 
displayed for the isotype control (black, narrow line), vehicle control (dotted line), EPA 
treated cultures (gray line), and ARA treated cultures (black, thick line). Both FA treated 
cultures display a small shift over to the right indicating a small increase in fluorescence 
of the F4/80 antigen, but the ARA treated cultures show a greater shift (more cells 
present in the higher fluorescence channels). Data represent the results from five 
independent experiments with the mean and SEM displayed. (*) indicates statistically 
significant (p-value < 0.05) difference based on one-way Kruskal-Wallis analysis of 
variance on ranks followed by Dunnett test. (**) indicates statistically significant (p-
value < 0.05) difference based on Student’s t-test without multiple comparison 
adjustment. 
 
Discussion 
 Our primary objective of this study was to determine if the reduction of later 
myeloid progenitor subtypes by diets high in n-3 FAs seen previously [12] was the 
continuation of differences induced at earlier stages of myeloid progenitor development. 
The data from these experiments indicate that this is not the case. The effect of lowering 
the frequency of myeloid progenitors of the later stages in mice fed n-3 FA rich diet was 
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recapitulated in the present study, but we did not see a lowering of the stem/early 
progenitor cell fractions in the bone marrow. Conversely, we observed an increase in the 
common myeloid progenitor cell fraction with flow cytometry. Thus, the effects of n-3 
FAs on stem/progenitor cell biology in bone marrow are not a simple lowering of the 
overall frequency of these cell types. Determination of the exact mechanism of n-3 FA 
effects will entail studies at multiple levels of maturation in bone marrow. Possible 
mechanisms include effects through metabolites such as leukotrienes, resolvins, 
incorporation into cell signaling molecules such as hedgehog, or production of 
prostaglandins. Our data suggest that these mechanisms are eventually triggering a 
slowed differentiation between the early and middle myeloid progenitor phases resulting 
in an increase in early progenitors and a decrease in later stage progenitors in high n-3 
diets. Understanding the mechanisms involved will enable targeted therapies for 
hematopoietic disorders involving problematic differentiation. 
 Our in vivo studies indicate that diets rich in n-3 FAs when compared to n-6 FAs 
have an effect of increasing the frequency of CMPs but no effect on HSCs (Fig 4.2). The 
changes seen in early stem/progenitor cell biology are then reversed, in that diets rich in 
n-6 FAs produce an increased number of later stage progenitor cells of the granulocyte 
and macrophage lineage (Fig 4.1). The results of our stem cell culture model found no 
lasting effects on stem cell viability or proliferation when cultured in n-3 vs. n-6 FAs 
(Fig. 4.4A), similar to that seen in vivo. It is interesting that we didn’t see an increase in 
HSCs with the corn oil diet containing high n-6 FA levels considering the recent results 
indicating one of the products of n-6 FAs, prostaglandin E2, can increase HSC 
production in vivo [19-22]. This may be due to the complex metabolism of FAs and the 
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use of them in biomolecules or to the genetics of the C57BL/6 model. We found a low 
level expression of F4/80 antigen upon treatment with ARA, characteristic of 
macrophage progenitor development [23-26], consistent with these progenitors being 
greater in vivo in corn oil fed mice compared to fish oil fed mice (Fig. 4.1). No other 
significant changes were seen in differentiation state upon treatment with ARA or EPA in 
comparison to vehicle controls. We observed a lower proliferation rate during 
differentiation of EML cells while cultured in EPA compared to vehicle controls that 
wasn’t seen with ARA treatment. This finding is consistent with an overall lowering of 
middle-later stage myeloid progenitor cell numbers in mice fed fish oil diets relative to 
corn oil diets (Fig.4.1). An important consideration in extrapolating these in vitro 
experiments to our in vivo results is that the EML cell model only takes into account cell 
autonomous factors. The stem cell niche is an important part of stem cell biology and it is 
not recapitulated in this model. 
These data indicate that the effect of n-3 FAs in the diet of mice on reducing later 
stage myeloid progenitors is not a simple reduction of HSCs in the bone marrow relative 
to n-6 FA fed mice. n-3 FAs appear to have a diverse effect depending upon the stage of 
progenitor cell development. Understanding the mechanisms involved will allow a more 
targeted approach to using n-3 FAs clinically in differentiation therapies. We are 
currently investigating whether the use of n-3 FAs as a mechanism of induced 
differentiation is applicable to reduction of the progression of chronic myelogenous 
leukemia (CML) to the lethal blast crisis phase in a murine model as well as clinical trials 
with B-cell malignancies ([27] and unpublished results). 
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Chapter 5: Discussion 
 
 Our research supports our hypotheses that genetic components as well as 
environmental components, specifically dietary fatty acids (FAs), regulate progenitor cell 
frequency. By understanding how hematopoiesis is influenced, we may better understand 
why it goes awry in hematological malignancies. In chapter 2, in silico mapping suggests 
that genes involved in the processes of lipid metabolism and bone remodeling play a key 
role in regulating myeloid progenitor cell frequency. In chapters 3 and 4, we show that 
the ratio of omega-3 (n-3) to omega-6 (n-6) FAs also plays a key role in this process. 
Both genetic and environmental components should be considered in attempts to identify 
mechanisms by which dysregulated hematopoiesis may lead to myeloproliferative 
diseases, myelodysplastic syndromes, and acute myelogenous leukemia (AML).  
 Identifying potential biomarkers and/or risk factors for AML prognosis is of value 
as alterations in the effects of these may give patients increased survival and lessened 
recurrence rate. Our data collectively suggest that FA content in the diet, metabolism, and 
bone properties are key regulators of hematopoiesis. Our in vivo and in vitro studies 
revealed that FA content in the diet has significant influence on myeloid progenitor cell 
frequency. Our genetics studies suggest that the way in which FAs are processed by the 
body also influences myeloid cell frequency. As insulin affects fat stores, it is not 
surprising that patterns of insulin related genes presented in chromosomal regions of high 
-logp values in our in silico study as well. Insulin stops the use of fat as an energy source 
and has a direct effect on FA synthesis in the body. Therefore, lack of control of insulin 
levels can have a profound effect on fat stores in the body [1]. Fat affects bone mineral 
density and bone volume [2]. The properties of the bone are part of the microenvironment 
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for hematopoiesis. Our research presents genes of interest as potential new biomarkers 
and risk factors in the areas of metabolism and bone properties for AML. The support for 
association of genes identified in our analysis is strong; however, causation must first be 
established in our system. 
 
In silico mapping studies 
 In silico mapping across 27 strains of inbred mice revealed patterns of genes 
located in chromosomal regions of the highest -logp values. Use of this method for 
identification of chromosomal loci containing genes of interest in regulating myeloid 
progenitor cell frequency was successful, as made evident by the high -logp value 
associated with the region of chromosome 14 containing interleukin 3 receptor alpha 
(IL3-R. This region served as a control for our study since the region presented in a 
previous study, and it is known that the IL3-R gene has a 5bp deletion in some mouse 
strains that results in lowered myeloid progenitor cell frequency [3, 4]. Additionally, loci 
in mouse chromosome 11 presented in our study are syntenic with the region of human 
chromosome 5 that undergoes deletion in a myelodysplastic syndrome called 5q- 
syndrome [5]. Additional genes contained within regions found in our study overlap with 
more traditional quantitative trait loci (QTL) studies for importance in stem and 
progenitor populations (Table 5.1) [6,7]. Our studies, however, show greater resolution. 
Though our results showed several smaller peaks of significance in chromosome 14, 
theses peaks span a large range, which is similar to the results found in previous 
traditional QTL studies (Fig. 5.1). A schematic representative of our resulting genes of 
interest is show in Figure 5.2. 
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Table 5.1: In silico mapping overlaps traditional QTL studies 
Previous QTLs Peaks of Interest in our In Silico Study 
4(37.6-48.5 and 66-78.5cM )  4(42.13-45.76cM and 74.75-75.77cM)  
9(23-27cM)  9(23.07-24.07cM)  
14 (broad range)  14(Several peaks within)  
  
Figure 5.1: Chromosome 14 contains a wide range of high peaks. The 9.17-18.48Mb 
region of chromosome 14 has a LOD (logarithm (base 10) of odds) score of 7.84. This 
image was created using data from in silico mapping in Chapter 2 (GEMM phenotype). 
Chromosome 14 9.17-18.48  
p-value 0.001-0.005 LOD 7.84 
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Figure 5.2: Schematic summary of resulting genes of interest from in silico mapping. 
Representative examples of mouse chromosomes 1-19 are shown. Regions of interest 
along chromosomes are indicated with red lines and blue bars. The GEMM phenotype 
has associations of interest with regions on chromosomes 5, 6, 7, 8, 14, and 18. The GM 
phenotype has associations of interest with regions on chromosomes 14 and 15. The E 
phenotype has associations of interest with regions on chromosomes 5, 9, and 11. The G 
phenotype has associations of interest with regions on chromosomes 8, 11, and 13. The 
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M phenotype has associations of interest with regions on chromosomes 2, 3, 11, 14, 15, 
18, and 19. The total phenotype has associations of interest with regions on chromosomes 
11 and 14. 
 
 In our goals of identifying loci associated with myeloid progenitor cell frequency 
as it relates to hematological malignancies, signaling pathway analysis was performed. 
Ingenuity Pathway Analysis (IPA) results showed the following pathways to be in the 
most significant for the top 50 genes found within chromosomal loci of the highest -logp 
values: gene expression, cancer, hematological disease, tumor morphology, genetic 
disorder, cell morphology, cell development, and cell cycle. As these are all important 
factors for leukemia, this further supports our method. In our literature searches, 30% of 
these top genes of interest were involved in cancer. Fifteen percent were associated 
specifically with leukemia. Eleven percent of genes were associated with hematopoiesis.  
Signaling networks from IPA also included many metabolic networks as well as 
reproductive system disease, and others. In completing literature searches on these genes 
as well, we found that 20% of genes had known association with dietary fat, FA uptake 
and oxidation, lipid metabolism, and atherosclerosis susceptibility. Atherosclerosis is a 
condition in which artery walls thicken as the result of a build-up of fatty materials. 
Nineteen percent of the top genes had association with insulin or diabetes. Eighteen 
percent had associations with bone properties. Many calcium and estradiol signaling 
genes presented in these top genes lists as well. This may be why the reproductive system 
disease presented as a top signaling pathway in IPA, as-estradiol is in the center of this 
network and is known to be vitally important in bone properties [8].   
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 Additional nodes or connection points in pathways of significance in IPA were 
transforming growth factor beta 1 (Tgf1) and hepatocyte nuclear factor 4 alpha (Hnf4). 
Tgf1 is known to be important to the process of hematopoiesis as it is a critical regulator 
for in vivo homeostasis of hematopoietic stem cells (HSCs), especially for their homing 
potential [9]. Furthermore, it has significant effects on bone. It functions to couple bone 
resorption and formation. Tgf1 released during bone resorption coordinates bone 
formation by inducing migration of bone marrow stromal cells to bone resorptive sites 
[10]. It also works to suppress osteoclast apoptosis [11]. Hnf4 is involved in 
coordinating the expression of genes involved in FA transport and metabolism [12]. 
Hnf4 regulated genes are also correlated with femur strength [13]. It has also been 
shown to serve as a molecular switch in transdifferentiation of hematopoietic cells to 
hepatocytes in vitro by decreasing myeloid colony-forming potential and increasing 
expression of hepatocyte-specific genes and proteins [14]. 
 Given these results and understanding of the relationships between insulin, 
metabolism, and bone properties, it will be interesting to determine if these processes, 
and the particular genes that presented in the chromosomal loci with the highest -logp 
values, in fact regulate hematopoiesis, with particular polymorphisms conferring 
susceptibility to hematological malignancies. Many insulin and diabetes associated genes 
in our study have been shown to have a major role in metabolism and bone remodeling 
[15-22]. As dietary fat content has been shown to regulate bone mineral density and bone 
volume, and as several QTLs for body size (body weight, length, and adipose mass) 
correlate with those identified for skeletal traits, there is evidence to suggest that many 
QTLs may regulate bone properties via their effect on body size [2,23]. Because the 
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microenvironment, including osteoclasts and osteoblasts, is highly involved in regulating 
hematopoiesis, it makes sense that the following process may be in effect (Fig. 5.3) [24]. 
Fat in the diet and how the body metabolizes and/or stores it along with the role of insulin 
in regulating fat stores and FA synthesis in the body, determine bone mineral density, 
which is the result of the work of competing osteoblasts and osteoclasts, each of which 
have effects on hematopoiesis [25-28]. Additionally, osteoclasts regulate insulin 
signaling in osteoblasts, which control whole body glucose homeostasis [29]. 
Furthermore, within the hematopoietic niche, marrow fat and bone mineral density are 
inversely related. Accelerated marrow adipogenesis has been associated with aging and, 
interestingly, diabetes mellitus and osteoporosis [30]. To address the importance of this 
component of the niche, Figure 5.4 shows the prevalence of adipocytes in a normal 
section of long bone.   
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Figure 5.3: Schematic for relationships of dietary fatty acids, insulin, metabolism, 
bone properties, and hematopoiesis. Omega FA content in the diet is involved in 
controlling glucose levels and regulating insulin sensitivity. Insulin stops use of fat as an 
energy source and promotes synthesis of FAs. Fat from the diet and lipid metabolism 
regulate bone mineral density among other bone properties. Osteoblast and osteoclast 
work against one another in controlling mineralization of the bone. Osteoclasts regulate 
insulin signaling in osteoblasts, which regulate whole body glucose homeostasis. The 
microenvironment regulates hematopoiesis. 
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Figure 5.4: Hematopoietic niche histology. This section of long bone illustrates the 
prevalence of adipocytes (large circular cells, example shown with asterisk) within the 
hematopoietic niche. This photo was taken using a Nikon Eclipse 80i microscope fitted 
with the SPOT Pursuit CCD camera (Diagnostic Instruments, Inc., Sterling Heights, MI) 
at 20X magnification. 
 
Dietary fatty acid studies  
 Corroborating the results of our in silico mapping studies, our studies of the effect 
of the diet on hematopoiesis revealed that dietary FA content significantly affects 
myeloid progenitor cell frequency. In our study of FVB X sv129 F1hybrid mice, we 
*
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found that a diet with higher n-3 FA content reduces total myeloid progenitor cell 
frequency and promotes differentiation of specific progenitor cell types in the bone 
marrow without having an adverse effect on levels of circulating white blood cells. Our 
data indicate that n-3 FA effects are particular to granulocyte and macrophage progenitor 
cells rather than erythrocyte maturation. Our results indicated a difference at the 
granulocyte macrophage (GM) progenitor stage and were suggestive, but inconclusive, of 
a difference at the granulocyte erythrocyte macrophage megakaryocyte (GEMM) stage. 
Our results presented the following question: is the reduction in middle and late stage 
progenitors by diets rich in n-3 FAs a continuation of differences induced at earlier stages 
of myeloid progenitor development? 
 Our second FA study addressed this question by investigating effects of dietary 
FAs at the earliest stem and progenitor cell stages of hematopoiesis. We examined the 
effects of n-3 and n-6 FAs in vivo in C57BL/6 mice, with an analysis at the level of stem 
and progenitor subtypes. Our results were consistent with the previous study in that 
compared to diets rich in n-6 FAs, diets rich in n-3 FAs induce lower levels of later stage 
myeloid progenitor cells in mice. We found, however, that reduction in late stage 
progenitor cells was not a continuation of any reduction in earlier progenitors or stem 
cells. Using flow cytometry, we found the common myeloid progenitor fraction was 
instead increased in these mice, suggesting that there are differentiation mechanisms 
responsible for an increase in early progenitors and a decrease in later stage progenitors 
in high n-3 diets. There was no difference in HSCs. 
 We performed in vitro studies as well to examine if the in vivo effects of n-3 and 
n-6 FAs could be modeled using the EML cell culture system to more readily ascertain 
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mechanisms involved. We found no lasting effects on stem cell viability or proliferation 
when cultured in n-3 vs. n-6 FAs, similar to that seen in vivo. We did find a low level 
expression of F4/80 antigen upon treatment with arachidonic acid (ARA) treatment, 
characteristic of macrophage progenitor development, and consistent with these 
progenitors being greater in vivo in corn oil fed mice compared to fish oil fed mice. No 
other significant changes were seen in differentiation state upon treatment with ARA or 
eicosapentanoic acid (EPA) in comparison to vehicle controls. Consistent with an overall 
lowering of middle-later stage myeloid progenitor cell numbers in mice fed fish oil diets 
relative to corn oil diets, in our in vitro model, we observed a lower proliferation rate 
during differentiation of cells cultured in EPA compared to vehicle controls that wasn’t 
seen with ARA treatment. Our conclusion was that the EML cell culture model was able 
to accurately model some aspects of FA effects on early hematopoietic stem and 
progenitor biology.  
 It is important, however, to realize that the EML cell model only takes into 
account cell autonomous factors. The hematopoietic microenvironment is an important 
part of stem cell and progenitor cell biology and this is not recapitulated in this model. As 
noted previously, dietary fat content has significant effects on bone mineral density, and 
osteoclasts and osteoblasts have been shown to affect hematopoiesis. A model without 
these factors present can give us only a limited idea of what is taking place at the whole 
organism level. Further research into the mechanisms controlling this complex regulation 
of stem and progenitor cell frequency by FAs may provide key information to target 
therapies to hematopoietic disorders.  
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In silico mapping and dietary fatty acid studies 
 We have found that there are chromosomal loci associated with myeloid 
progenitor frequency and that these loci present interesting patterns when examining the 
genes within them. We have found that dietary n-3 to n-6 FA ratios play a significant role 
in controlling progenitor cell frequency. After discovering these answers to the questions 
originally proposed, new questions are presented. What possible mechanisms exist that 
combine dietary FA content with patterns of metabolic pathways and bone properties for 
controlling myeloid frequency?  
 In attempting to answer this question, I am proposing new hypotheses. As n-3 
FAs have been associated with protective functions for osteoblastogenesis and they 
decrease osteoclastogenesis and osteoclast differentiation, I hypothesize that osteoblasts, 
protected by dietary n-3 FAs, subsequently upregulate granulocyte macrophage colony 
stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), and 
interleukin 6 (IL-6), which are responsible for the differentiation of hematopoietic cells 
toward the monocyte and granulocyte lineages [26, 31-32]. If this is true, as these 
cytokines work to differentiate these cells, there would be fewer cells in progenitor stages 
than those in n-6 FA rich diets. Because these cytokines promote granulocyte and 
monocyte differentiation, there would be no decrease in erythrocyte progenitors than 
when compared to n-6 FA rich diets, which would corroborate the results in our dietary 
FA studies (Fig.5.5).  In order to address the result of increased common myeloid 
progenitors (CMPs) in mice fed n-3 FA rich diets, I additionally hypothesize that the 
push of HSCs toward the myeloid lineage by the presence of these cytokines creates an 
initial increase in CMPs when compared to a diet rich in n-6 FAs in which HSCs are 
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producing an even mix of common lymphocyte progenitors and CMPs. Additionally, the 
n-6 FA metabolite prostaglandin E2 (PGE2) significantly lowers macrophage colony 
stimulating factor (M-CSF) secretion by bone marrow stromal cells, further supporting 
this idea [33]. 
n-3 FA Rich Diet 
Protected 
Osteoblastogenesis 
Decreased 
Osteoclastogenesis 
GM-CSF
IL-6
G-CSF
HSC
MPP
CMP
Granulocyte and 
Monocyte Lineages
 
 Figure 5.5: Influence of n-3 FA rich diet on myeloid progenitor cell frequency. n-3 
FAs protect osteoblastogenesis and prevent osteoclastogenesis. Cytokines released by the 
osteoblasts stimulate multi-potential progenitors (MPPs) to differentiate to the myeloid 
lineage and continue to differentiate these cells into granulocytes and monocytes.  
 
 This finding also presents the idea that if cytokines that support differentiation of 
these progenitors are being suppressed in n-6 rich FA diets, these progenitor cells are 
given more time in this stage to acquire mutations. Current theory for the acquiring of 
leukemia suggests that failure of progenitors to differentiate causes prolonged 
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proliferation, thereby increasing the chances that these cells will accumulate events 
contributing to cancer progression [34]. On a side note, IL-6, is additionally produced in 
the working muscle during physical activity and has been proposed to act as an energy 
sensor by enhancing glucose disposal, lipolysis, and fat oxidation [35]. Perhaps this 
accounts for an additional role of physical activity in regulating hematopoiesis. 
 Determination of the exact mechanism of n-3 and n-6 FA effects will entail 
studies at multiple levels of maturation in bone marrow. Mechanisms by which n-3 FAs 
have been shown to inhibit proliferation, induce apoptosis, and promote differentiation in 
many cancers include the regulation of signaling pathways and gene expression by 
peroxisome proliferator receptor activator γ (PPARγ), for which n-3 FAs are natural 
ligands [36]. Ligand activation of the PPAR-RXR heterodimer complex enhances 
insulin sensitivity. Insulin levels affect fat stores, which in turn affect bone composition. 
PPAR has also been shown to control bone formation and bone mass through the 
modulation of bone marrow stromal cell differentiation [37]. Another mechanism of 
action of n-3 FAs includes inhibition of cyclooxygenase 2 (COX2), which is upregulated 
in various cancers and is known to have proproliferative and antiapoptotic effects [38-
46]. COX2 was shown to significantly increase the rate of osteoclast formation in breast 
cancer studies [47]. Additional possible mechanisms include effects through metabolites 
such as leukotrienes, resolvins, incorporation into cell signaling molecules such as 
hedgehog, or production of prostaglandins. 
 Overall, our studies show that dietary FAs affect myeloid progenitor cell 
frequency. They suggest that metabolism and bone properties regulate myeloid 
progenitor cell frequency as well. As dietary intake and insulin regulate fat stores in the 
133 
body, fat regulates bone mineral density, and bone microenvironment influences 
hematopoiesis, these processes and the genes that control them should be further 
investigated in regulating myeloid progenitor cell frequency as it is pertinent to 
hematological diseases. As diet is controllable and bone mineral density is fairly easy and 
inexpensive to assess, these have great potential to serve as new therapies and risk 
prognosis indicators in AML.  
 Future directions for our lab will include determining if genes located in 
chromosomal regions with high -logp values are in fact associated with changes in 
myeloid progenitor cell frequency. Our lab will identify these genes through deep 
sequencing and determine if evidence supports a causal relationship to myeloid 
progenitor frequency in congenic strains. Our lab will also determine if the particular 
pathways that emerged the most (bone properties and metabolic processes) are 
biomarkers for AML progression risk by assaying mice for parameters associated with 
these pathways and determining correlation with myeloid progenitor cell frequency.  
Additionally, the validation of the role of these genes and pathways in human 
hematopoiesis and AML progression will take place. Bone marrow from AML patients 
and normal individuals will be analyzed to determine if the genes and pathways identified 
in mice translate to humans. Experiments involving the novel hypotheses presented in 
regard to the overall relationships of the FA content in the diet, its effects on bone, and 
therefore cytokines secreted in the hematopoietic microenvironment may also be pursued. 
Upon subjection to corn or fish oil diet, mice will be assessed for parameters of bone 
composition, cytokines in the hematopoietic microenvironment, and hematopoietic stem 
and progenitor cell frequencies, including common lymphoid progenitors. Once 
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correlation has been established, further investigation into mechanisms of action such as 
PPAR activation or COX2 inhibition will pursued. 
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